US20230301994A9 - Bicyclic compounds and methods for their use in treating pitt hopkins syndrome - Google Patents
Bicyclic compounds and methods for their use in treating pitt hopkins syndrome Download PDFInfo
- Publication number
- US20230301994A9 US20230301994A9 US17/770,690 US202017770690A US2023301994A9 US 20230301994 A9 US20230301994 A9 US 20230301994A9 US 202017770690 A US202017770690 A US 202017770690A US 2023301994 A9 US2023301994 A9 US 2023301994A9
- Authority
- US
- United States
- Prior art keywords
- allylp
- tcf4
- compound
- substituted
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 201000004317 Pitt-Hopkins syndrome Diseases 0.000 title claims abstract description 68
- 125000002619 bicyclic group Chemical group 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 93
- -1 cyclic Glycyl Proline compounds Chemical class 0.000 claims abstract description 49
- 208000024891 symptom Diseases 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 68
- 230000003247 decreasing effect Effects 0.000 claims description 57
- 241001465754 Metazoa Species 0.000 claims description 52
- 230000006399 behavior Effects 0.000 claims description 51
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 41
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 39
- 230000002159 abnormal effect Effects 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000003342 alkenyl group Chemical group 0.000 claims description 31
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 230000006735 deficit Effects 0.000 claims description 22
- 230000015654 memory Effects 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 20
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 20
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 20
- 208000035475 disorder Diseases 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 19
- 230000033001 locomotion Effects 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 230000003750 conditioning effect Effects 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 14
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 14
- 208000019901 Anxiety disease Diseases 0.000 claims description 13
- 230000036506 anxiety Effects 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 13
- 125000003107 substituted aryl group Chemical group 0.000 claims description 13
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 13
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 claims description 12
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 12
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 12
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 10
- 239000004090 neuroprotective agent Substances 0.000 claims description 10
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 9
- 230000000421 anti-necrotic effect Effects 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 108010059616 Activins Proteins 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 206010010904 Convulsion Diseases 0.000 claims description 7
- 108010051696 Growth Hormone Proteins 0.000 claims description 7
- 102400001066 Growth hormone-binding protein Human genes 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 7
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 claims description 7
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 claims description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 7
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 7
- 102000004230 Neurotrophin 3 Human genes 0.000 claims description 7
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 7
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 230000001594 aberrant effect Effects 0.000 claims description 7
- 239000000488 activin Substances 0.000 claims description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 230000001149 cognitive effect Effects 0.000 claims description 7
- 239000000122 growth hormone Substances 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 229940053128 nerve growth factor Drugs 0.000 claims description 7
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 7
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 7
- 230000003252 repetitive effect Effects 0.000 claims description 7
- 108010033419 somatotropin-binding protein Proteins 0.000 claims description 7
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 6
- QUCFVNGGGFLOES-ACQYNFKHSA-N (4s)-5-[[(2s)-1-[[(2s)-1-[[(2r)-6-amino-1-[[(1s)-1-carboxy-2-phenylethyl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2s)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCS(=O)(=O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 QUCFVNGGGFLOES-ACQYNFKHSA-N 0.000 claims description 6
- MGNMVYXIKDNAKK-UHFFFAOYSA-N 3,3-bis(3-fluorophenyl)-n-methylpropan-1-amine;hydron;chloride Chemical compound Cl.C=1C=CC(F)=CC=1C(CCNC)C1=CC=CC(F)=C1 MGNMVYXIKDNAKK-UHFFFAOYSA-N 0.000 claims description 6
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims description 6
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 6
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 6
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 6
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 claims description 6
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 6
- 108050003237 Fibroblast growth factor 11 Proteins 0.000 claims description 6
- 102100028413 Fibroblast growth factor 11 Human genes 0.000 claims description 6
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims description 6
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 claims description 6
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims description 6
- 108090000046 Fibroblast growth factor 14 Proteins 0.000 claims description 6
- 102100035292 Fibroblast growth factor 14 Human genes 0.000 claims description 6
- 108050002072 Fibroblast growth factor 16 Proteins 0.000 claims description 6
- 102100035307 Fibroblast growth factor 16 Human genes 0.000 claims description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 6
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 6
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 6
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 6
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 6
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 6
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 6
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 6
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 6
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 6
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 claims description 6
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims description 6
- 102000003957 Fibroblast growth factor 9 Human genes 0.000 claims description 6
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 6
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 6
- 102000006992 Interferon-alpha Human genes 0.000 claims description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims description 6
- 102000003996 Interferon-beta Human genes 0.000 claims description 6
- 108090000467 Interferon-beta Proteins 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 claims description 6
- 102000004140 Oncostatin M Human genes 0.000 claims description 6
- 108090000630 Oncostatin M Proteins 0.000 claims description 6
- 108010038109 Org 2766 Proteins 0.000 claims description 6
- 108700019404 Pro-Gly-Pro- ACTH (4-7) Proteins 0.000 claims description 6
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
- 108010027834 activity-dependent neurotrophic factor Proteins 0.000 claims description 6
- 108010046910 brain-derived growth factor Proteins 0.000 claims description 6
- 229960004414 clomethiazole Drugs 0.000 claims description 6
- 230000001667 episodic effect Effects 0.000 claims description 6
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 6
- 229940044627 gamma-interferon Drugs 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 230000007787 long-term memory Effects 0.000 claims description 6
- HVJHJOYQTSEKPK-UHFFFAOYSA-N n-(1-hydroxy-3-morpholin-4-yl-1-phenylpropan-2-yl)decanamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(O)C(NC(=O)CCCCCCCCC)CN1CCOCC1 HVJHJOYQTSEKPK-UHFFFAOYSA-N 0.000 claims description 6
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 6
- 229960003946 selegiline Drugs 0.000 claims description 6
- AFEHBIGDWIGTEH-AQRCPPRCSA-N semax Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CNC=N1 AFEHBIGDWIGTEH-AQRCPPRCSA-N 0.000 claims description 6
- 230000006403 short-term memory Effects 0.000 claims description 6
- 230000011273 social behavior Effects 0.000 claims description 6
- 229960001967 tacrolimus Drugs 0.000 claims description 6
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 6
- 208000000044 Amnesia Diseases 0.000 claims description 5
- 208000026139 Memory disease Diseases 0.000 claims description 5
- 230000036471 bradycardia Effects 0.000 claims description 5
- 208000006218 bradycardia Diseases 0.000 claims description 5
- 230000001073 episodic memory Effects 0.000 claims description 5
- 238000013507 mapping Methods 0.000 claims description 5
- 230000006984 memory degeneration Effects 0.000 claims description 5
- 208000023060 memory loss Diseases 0.000 claims description 5
- 230000006886 spatial memory Effects 0.000 claims description 5
- 230000000946 synaptic effect Effects 0.000 claims description 5
- 230000003044 adaptive effect Effects 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 230000004217 heart function Effects 0.000 claims description 3
- 230000000422 nocturnal effect Effects 0.000 claims description 3
- 230000004202 respiratory function Effects 0.000 claims description 3
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 50
- 239000000499 gel Substances 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 239000003826 tablet Substances 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 101150017815 TCF4 gene Proteins 0.000 description 141
- 239000003981 vehicle Substances 0.000 description 98
- 241000699670 Mus sp. Species 0.000 description 90
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 56
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 38
- WVKCGUOWPZAROG-JTQLQIEISA-N (8ar)-8a-prop-2-enyl-3,6,7,8-tetrahydro-2h-pyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)[C@@]2(CC=C)N1CCC2 WVKCGUOWPZAROG-JTQLQIEISA-N 0.000 description 23
- 108010063841 cyclo-L-glycyl-L-2-allylproline Proteins 0.000 description 23
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 108010048992 Transcription Factor 4 Proteins 0.000 description 17
- 102100023489 Transcription factor 4 Human genes 0.000 description 17
- 238000000540 analysis of variance Methods 0.000 description 17
- 230000035772 mutation Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 230000008014 freezing Effects 0.000 description 14
- 238000007710 freezing Methods 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 206010003805 Autism Diseases 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 238000004891 communication Methods 0.000 description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- 208000020706 Autistic disease Diseases 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 206010011953 Decreased activity Diseases 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000010408 film Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 6
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 6
- 102100038803 Somatotropin Human genes 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000003989 repetitive behavior Effects 0.000 description 6
- 208000013406 repetitive behavior Diseases 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 208000029560 autism spectrum disease Diseases 0.000 description 5
- 230000003370 grooming effect Effects 0.000 description 5
- 230000013016 learning Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 4
- UZRXLKFQBCCVJH-UHFFFAOYSA-N 1-(phenylmethoxycarbonylamino)cyclohexane-1-carboxylic acid Chemical compound C=1C=CC=CC=1COC(=O)NC1(C(=O)O)CCCCC1 UZRXLKFQBCCVJH-UHFFFAOYSA-N 0.000 description 4
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 206010001488 Aggression Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100023206 Neuromodulin Human genes 0.000 description 4
- 101710144282 Neuromodulin Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 102000004874 Synaptophysin Human genes 0.000 description 4
- 108090001076 Synaptophysin Proteins 0.000 description 4
- 238000010162 Tukey test Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 4
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000003997 social interaction Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 3
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 3
- 201000006347 Intellectual Disability Diseases 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000004766 neurogenesis Effects 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 244000062645 predators Species 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940122459 Glutamate antagonist Drugs 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000033712 Self injurious behaviour Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 210000003520 dendritic spine Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- SNCDZWDDKDMUES-UHFFFAOYSA-N octan-4-one Chemical compound [CH2]CCCC(=O)CCC SNCDZWDDKDMUES-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 231100000812 repeated exposure Toxicity 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- OWOHLURDBZHNGG-YFKPBYRVSA-N (8ar)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)[C@@H]2CCCN12 OWOHLURDBZHNGG-YFKPBYRVSA-N 0.000 description 1
- LERUHVMGZCJXLR-LURJTMIESA-N (8as)-2-methyl-6,7,8,8a-tetrahydro-3h-pyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1N(C)CC(=O)N2CCC[C@H]21 LERUHVMGZCJXLR-LURJTMIESA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- IXXMJXGMYKDTRQ-UHFFFAOYSA-N 1-(phenylmethoxycarbonylamino)cyclopentane-1-carboxylic acid Chemical compound C=1C=CC=CC=1COC(=O)NC1(C(=O)O)CCCC1 IXXMJXGMYKDTRQ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 102100022142 Achaete-scute homolog 1 Human genes 0.000 description 1
- 102000007476 Activating Transcription Factor 3 Human genes 0.000 description 1
- 108010085371 Activating Transcription Factor 3 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101150029001 CDH2 gene Proteins 0.000 description 1
- 102100025492 CUGBP Elav-like family member 3 Human genes 0.000 description 1
- 101710170319 CUGBP Elav-like family member 3 Proteins 0.000 description 1
- 102100025488 CUGBP Elav-like family member 4 Human genes 0.000 description 1
- 101710170352 CUGBP Elav-like family member 4 Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101150004620 Cebpb gene Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 101150029544 Crem gene Proteins 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150114117 EGR1 gene Proteins 0.000 description 1
- 108010051542 Early Growth Response Protein 1 Proteins 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 102100026801 Glycophorin-E Human genes 0.000 description 1
- 101150087728 Grm5 gene Proteins 0.000 description 1
- 101000901099 Homo sapiens Achaete-scute homolog 1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000701142 Homo sapiens Transcription factor ATOH1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 description 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 1
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 1
- CJUMAFVKTCBCJK-UHFFFAOYSA-N N-benzyloxycarbonylglycine Chemical compound OC(=O)CNC(=O)OCC1=CC=CC=C1 CJUMAFVKTCBCJK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101150079937 NEUROD1 gene Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101150088803 NR4A1 gene Proteins 0.000 description 1
- 101150036143 NTF3 gene Proteins 0.000 description 1
- 101150115130 NTF4 gene Proteins 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108700020297 NeuroD Proteins 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 102100032063 Neurogenic differentiation factor 1 Human genes 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 101710092553 Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150083342 PPP3CA gene Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101150056812 Pcdh8 gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710128487 Pre-mRNA leakage protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100034958 Protocadherin-8 Human genes 0.000 description 1
- 101710141456 Protocadherin-8 Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 101100230601 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HBT1 gene Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100029373 Transcription factor ATOH1 Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 101100405120 Xenopus laevis nr4a1 gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 239000003004 anti necrotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035045 associative learning Effects 0.000 description 1
- 230000001042 autoregulative effect Effects 0.000 description 1
- 239000008228 bacteriostatic water for injection Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 108010029829 cyclic glycine-proline Proteins 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004914 glial activation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000021061 grooming behavior Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010043603 integrin alpha4beta7 Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GCHPUFAZSONQIV-UHFFFAOYSA-N isovaline Chemical compound CCC(C)(N)C(O)=O GCHPUFAZSONQIV-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000007542 postnatal development Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940119265 sepp Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004036 social memory Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008184 synaptic development Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Arylalkyl refers to a straight chain alkyl, alkenyl or alkynyl group wherein one of the hydrogen atoms bound to the terminal carbon is replaced with an aryl group.
- exemplary arylalkyl groups include benzyl, naphthylmethyl, benzylidene and the like.
- Ne4a1 means Nuclear Receptor Subfamily 4 Group A member 1, also known as Nerve Growth Factor IB.
- compositions and methods of the invention find use in the treatment of animals, such as human patients, suffering from cognitive impairment and symptoms associated with Pitt Hopkins Syndrome. Still more generally, the compositions and methods of the disclosure find use in the treatment of mammals, such as human patients, suffering from memory impairment, intellectual disability, impaired social interaction, impairments in language and communication, impaired motor function, restricted and repetitive interests and behaviours, abnormal sleep behaviors, other aberrant behaviors and seizures.
- therapeutic agents include, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, andrenocorticotropin-(4-9) analog (ORG 2766), dizolcipine (MK-801), selegiline; glutamate antagonists, NPS1506, GV1505260, MK-801, GV150526; AMPA antagonists, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070, LY300164, anti-inflammatory agents directed against the addressin MAdCAM-1 and/or its integrin ⁇ 4 receptors ( ⁇ 4 ⁇ 1 and ⁇ 4 ⁇ 7), anti-MAdCAM-1mAb MECA-367 (ATCC accession no. HB-9478).
- X 1 , X 3 , and X 4 are independently selected from the group consisting of S, O, and NH;
- Embodiment 5 A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound of the formula:
- Embodiment 17 The method of any of embodiments 1 to 13, further comprising administering at least one other anti-apoptotic, anti-necrotic or neuroprotective agent.
- Embodiment 32 The method of any of embodiments 1 to 31, where assessment of efficacy is via measurement of phosphorylated ERK (pERK) or phosphorylated Akt (pAkt) in lymphocytes of the animal, where normalization of either pERK or pAkt indicates reduction in severity of said disorder.
- pERK phosphorylated ERK
- pAkt phosphorylated Akt
- Embodiment 48 The use of any of Embodiments 40 to 47, where the use further comprises said compound with a pharmaceutically acceptable excipient and a binder.
- Tcf4 +/ ⁇ mice treated with vehicle only built nexts of substantially lower quality.
- WT animals treated with either 100 mg/kg (NNZ-2591 (cG-2-AllylP; third column from left or 200 mg/kg (fifth column from left) built nests of quality nearly identical to those of vehicle-treated WT mice.
- Tcf4 +/ ⁇ mice treated with either 100 mg/kg (fourth column from left) or 200 mg/kg NNZ-2591 (cG-2-AllylP; right column) normalized the quality of nests to levels nearly identical to WT mice.
- the differences in quality of nests built by the Tcf4 +/ ⁇ mice treated with NNZ-2591 were substantially and statistically significantly better than those built by the Tcf4 +/ ⁇ mice treated with vehicle only.
- Hind limb force is an important measure of the ability of a mouse to jump away from a predator. However, animals with the Tcf4 +/ ⁇ mutation have substantially lower ability to jump away from a predator, making this mutation very serious and potentially life threatening. Hind limb force is also considered a surrogate for motor function in humans. To determine if NNZ-2591 (cG-2-AllylP) might provide a helpful treatment for this condition, we carried out a series of studies in which we measured hind limb force. These results are shown in FIG. 7 . The vertical axis shows the force in Newtons (N), and the horizontal axis shows the animals and treatments.
- N Newtons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Embodiments of this invention provide compounds, compositions, methods, and uses for therapeutic diketopiperazines, including cyclic G-2-Allyl Proline and other cyclic Glycyl Proline compounds to treat Pitt Hopkins Syndrome and symptoms thereof, as well as manufacture of compositions, medicaments including tablets, capsules, liquid formulations, gels, injectable solutions, and other formulations that are useful for treatment of such conditions.
Description
- This PCT International Patent Application claims priority to U.S. Provisional Patent Application No. 62/924,452 filed 22 Oct. 2019 and relates to bicyclic compounds structurally related to diketopiperazines and methods for their therapeutic use in treating Pitt Hopkins Syndrome. For example, this disclosure relates to the use of cyclic Glycyl Proline (“cGP”) and analogs thereof, including cyclic Glycyl-2-Allyl Proline (“cyclic G-2-AllylP” or “cG-2-AllylP”), cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP, and/or related compounds and pharmaceutical compositions thereof in the treatment of Pitt Hopkins Syndrome (PTHS). The Provisional Patent Application is incorporated herein fully by reference.
- Pitt Hopkins syndrome (PTHS) is a rare genetic condition caused by heterozygous hypomorphic or null mutation or deletion of the transcription factor 4 (TCF4) gene on human chromosome 18q21.1 (Sweatt, 2013). TCF4 haploinsufficiency has been proposed as an underlying mechanism for PTHS. TCF4 encodes a basic helix-loop-helix (bHLH) transcription factor that is known to heterodimerize with several other bHLH transcription factors that play important roles in neurogenesis and neuronal migration in the brain. There currently is no cure or treatment specifically for PTHS.
- Pitt Hopkins syndrome (PTHS) is characterized by significant developmental delays with moderate-to-severe intellectual disability and behavioral differences, characteristic facial features, and episodic hyperventilation and/or breath-holding while awake. Speech is significantly delayed and most individuals are nonverbal with receptive language often stronger than expressive language. Other common findings are autism spectrum disorder symptoms, sleep disturbance, stereotypic hand movements, seizures, constipation, and severe myopia (Sweetser et al, 2012).
- Formal prevalence studies have not been conducted so the true prevalence of PTHS has not been established. Rosenfeld et al, (2009) estimated the frequency of chromosome 18q21 deletions associated with PTHS is between 1:34,000 and 1:41,000. Sweetser et al, (2012) note that if deletions are found in approximately one third of individuals with PTHS, the frequency of the condition could be as high as 1:11,000. According to the range of prevalence estimates above, if the US population is currently at least 327,167,434 (US Census 2018), then between 8000 and 30,000 US citizens may be affected by PTHS.
- Pitt Hopkins syndrome affects both males and females and can affect individuals of any ethnic or racial background. Approximately 1000 affected individuals have been enrolled in a patient registry by the Pitt Hopkins Foundation.
- Pitt Hopkins Syndrome is a severely limiting disorder in which affected individuals rarely achieve the functional capacity to care for themselves, protect themselves from harm, form normal adult relationships, or achieve gainful employment. Such a severe disability results in significant costs for medical and supportive care. The condition is also associated with challenging behaviors that create acute and chronic stress for caregivers. There are no approved products indicated for the treatment of PTHS.
- We have found a new problem in the field, namely how to effectively treat Pitt Hopkins Syndrome. To do this, we studied the effects of certain analogs of diketopiperazines in an animal model of Pitt Hopkins Syndrome (PTHS). Mice having mutations of the tcf4 (TCF4) gene and mice without the mutation were studied in a controlled trial. Because tcf4 mutant mice exhibit features of PTHS, studies of the effects of the diketopiperazines, cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and related cyclic piperidines are predictive of effects in human beings with PTHS.
- Therefore, we treat patients with PTHS with cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP or related cyclic piperidines to circumvent the TCF4 deficiency, mimicking the natural actions of cGP by rescuing the abnormal dendritic morphology and stimulating protein synthesis in excitatory synapses through, but not necessarily exclusively through, the following mechanisms:
- 1. Reducing neuroinflammation and pathological glial activation;
- 2. Normalizing AKT expression and activation upstream of mTOR in the PI3K-AKT-mTOR pathway;
- 3. Normalizing ERK expression and activation in the MAPK-ERK signaling pathway; and/or
- 4. Restoring normal levels and/or bioavailability of IGF-1.
- As described below, oral administration of cG-2-AllylP for 6 weeks can rescue the phenotype of the Tcf4+/− knockout mouse model of PTHS, while having no impact on wild type control mice.
- Cyclic GP is cG-2-AllylP and related compounds are shown as
formula 1 - In some aspects, compounds of Formula 1 include substituents where:
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6; or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6; with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and; when R1═H, at least one of R2 and R3≠H.
- In further aspects, this invention provides a compound of
Formula 1 or a pharmaceutically acceptable salt, stereoisomer or hydrate thereof, wherein R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2 (cyclic Glycyl-2-AllylProline). - In still other aspects, this invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of cyclic G-2-AllylP.
- In further aspects, this invention provides methods of treating an animal having a cognitive impairment, comprising administration to that animal an effective amount of a composition comprising cyclic G-2-AllylP. In yet further aspects, the animal to be treated is a human.
- This disclosure is described with reference to specific embodiments thereof. Other aspects of this invention can be appreciated with reference to the drawings, in which:
-
FIG. 1 depicts the chemical structure of cG-2-AllylP. -
FIG. 2 is a graph showing the results of an open field study of the effects of cG-2-AllylP or vehicle in mice having the tcf4+/− mutation on hypoactivity (distance travelled) compared to wild type mice. -
FIG. 3 is a graph showing results from studies of the effects of cG-2-AllylP or vehicle in mice having the tcf4+/− mutation on repetitive behavior (the time spent self grooming) compared to wild type mice. -
FIG. 4 is a graph showing results of studies of the effects of the effects of cG-2-AllylP or vehicle in mice having the tcf4+/− mutation on fear conditioning (time freezing in place) compared to wild type mice. -
FIG. 5 is a graph showing results of studies of the effects of the effects of cG-2-AllylP or vehicle in mice having the tcf4+/− mutation on sociability (time spent with novel mouse) compared to wild type mice. -
FIG. 6 is a graph showing results of studies of the effects of the effects of cG-2-AllylP or vehicle in mice having the tcf4+/− mutation on daily living (nest building) compared to wild type mice. -
FIG. 7 is a graph showing results of studies of the effects of the effects of cG-2-AllylP or vehicle in mice having the tcf4+/− mutation on motor performance (hind limb force) compared to wild type mice. - “Alkenyl” refers to an unsaturated branched, straight chain or cyclic hydrocarbon radical having at least one carbon-carbon double bond. The radical may be in either the cis or trans conformation about the double bond(s). Exemplary alkenyl groups include allyl, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, cyclopentenyl and the like. In some embodiments the alkenyl groups are (C2-C6) alkenyl, and in other embodiments, allyl can be particularly useful.
- “Alkyl” refers to a saturated branched, straight chain or cyclic hydrocarbon radical. Exemplary alkyl groups include methyl, ethyl, isopropyl, cyclopropyl, tert-butyl, cyclopropylmethyl, hexyl and the like. In some embodiments the alkyl groups are (C1-C6) alkyl.
- “Alkynyl” refers to an unsaturated branched, straight chain or cyclic hydrocarbon radical having at least one carbon-carbon triple bond. Exemplary alkynyl groups include ethynyl, propynyl, butynyl, isobutynyl and the like. In some embodiments the alkynyl group is (C2-C6) alkynyl.
- “Aryl” refers to an unsaturated cyclic hydrocarbon radical with a conjugated π electron system. Exemplary aryl groups include phenyl, naphthyl and the like. In some embodiments the aryl group is (C5-C20) aryl.
- “Arylalkyl” refers to a straight chain alkyl, alkenyl or alkynyl group wherein one of the hydrogen atoms bound to the terminal carbon is replaced with an aryl group. Exemplary arylalkyl groups include benzyl, naphthylmethyl, benzylidene and the like.
- “Cognitive impairment“and” cognitive dysfunction” means one or more signs or symptoms of memory loss, loss of spatial orientation, decreased ability to learn, decreased ability to form short- or long-term memory, decreased episodic memory, decreased ability to consolidate memory, decreased spatial memory, decreased receptive language and/or communication, decreased expressive language and/or communication, decreased synaptogenesis, decreased synaptic stability, deficits in executive function, deficits in cognitive mapping and scene memory, deficits in declarative and relational memory, decreased rapid acquisition of configural or conjunctive associations, decreased context-specific encoding and retrieval of specific events, decreased episodic and/or episodic-like memory, anxiety, abnormal fear conditioning, abnormal social behaviour, repetitive behaviour, restrictive behavior, abnormal sleep behavior, aggressive behaviour, self-injurious behaviour, stereotypic hand movements, temper tantrums, seizure activity, abnormal locomotion, abnormal expression or activation of ERK1/2 or and Akt, and bradycardia.
- “Comprising,” and “Comprises” means including, but not limited to the elements listed.
- “Consisting of” means including the elements listed and no others.
- “Consisting essentially of” means including the elements listed and their equivalents.
- “Growth factor” refers to an extracellularly active polypeptide that stimulates a cell to grow or proliferate by interacting with a receptor on the cell.
- “Heteroalkyl” refers to an alkyl moiety wherein one or more carbon atoms are replaced with another atom such as N, P, O, S etc. Exemplary heteroalkyl groups include pyrrolidine, morpholine, piperidine, piperazine, imidazolidine, pyrazolidine, tetrahydrofuran, (C1-C10) substituted amines, (C2-C6) thioethers and the like.
- “Heteroaryl” refers to an aryl moiety wherein one or more carbon atoms are replaced with another atom such as N, P, O, S etc. Exemplary heteroaryl groups include carbazole, furan, imidazole, indazole, indole, isoquinoline, purine, pyrazine, pyrazole, pyridazine, pyridine, pyrrole, thiazole, thiophene, triazole and the like.
- “Pharmaceutically acceptable excipient” refers to an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, or, in the case of an aerosol composition, gaseous.
- “Pharmaceutically acceptable salt” refers to a salt that is pharmaceutically acceptable and has the desired pharmacological properties. Such salts include salts that may be formed where acidic protons present in the compounds are capable of reacting with inorganic or organic bases. Suitable inorganic salts include those formed with the alkali metals, e.g. sodium and potassium, magnesium, calcium, and aluminium. Suitable organic salts include those formed with organic bases such as the amine bases e.g. ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Such salts also include acid addition salts formed with inorganic acids (e.g. hydrochloric and hydrobromic acids) and organic acids (e.g. acetic acid, citric acid, maleic acid, and the alkane- and arene-sulfonic acids such as methanesulfonic acid and benzenesulfonic acid).
- When there are two acidic groups present, a pharmaceutically acceptable salt may be a mono-acid mono-salt or a di-acid salt; and similarly where there are more than two acidic groups present, some or all of such groups can be present as salts.
- “Protecting group” has the meaning conventionally associated with it in organic synthesis, i.e. a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete.
- “Stereoisomer” is a molecule having the structure of cyclic G-2-Allyl Proline, but having a chiral center. The term “cyclic G-2-Allyl Proline” includes all stereoisomers.
- “Substituted” refers to where one or more of the hydrogen atoms on an alkyl, heteroalkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl radical are independently replaced with another substituent. Substituents include —R′, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, —NR′—C(NR′)—OR′, —NR′—C(NR′)—SR′, NR′—C(NR′)—NR′R′, trihalomethyl and halogen where each R′ is independently —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl.
- “Symptom” or “symptoms” means one or more of cognitive impairment or cognitive dysfunction, one or more signs or symptoms of memory loss, loss of spatial orientation, decreased ability to learn, decreased ability to form short- or long-term memory, decreased episodic memory, decreased ability to consolidate memory, decreased spatial memory, decreased receptive language and/or communication, decreased expressive language and/or communication, decreased synaptogenesis, decreased synaptic stability, deficits in executive function, deficits in cognitive mapping and scene memory, deficits in declarative and relational memory, decreased rapid acquisition of configural or conjunctive associations, decreased context-specific encoding and retrieval of specific events, decreased episodic and/or episodic-like memory, anxiety, abnormal fear conditioning, abnormal social behaviour, repetitive behaviour, restrictive behavior, abnormal sleep behavior, aggressive behaviour, self-injurious behaviour, stereotypic hand movements, temper tantrums, seizure activity, abnormal locomotion, abnormal expression or activation of ERK1/2 or and Akt, and bradycardia.
- “Therapeutically effective amount” means the amount that, when administered to an animal for treating a disease, is sufficient to effect treatment for a disease. A “therapeutically effective amount” means an amount that decreases adverse symptoms or findings, promotes desirable symptoms or findings, and/or treats an underlying disorder, and/or is curative.
- “Treating” or “treatment” of a disease includes prophylaxsis, meaning inhibiting a symptom of the disease in an animal that may be predisposed to the disease but does not yet experience or exhibit symptoms of the disease, inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease). Treatment does not include correcting genetic abnormalities of Pitt Hopkins Syndrome.
- Implicit hydrogen atoms (such as the hydrogens on the pyrrole ring, etc.) are omitted from the formulae for clarity, but should be understood to be present.
- “ATF3” means Activating Transcription Factor 3.
- “IL1-beta” means Interleukin 1-beta.
- “IL-6” means Interleukin-6.
- “BDNF” means Brain Derived Neurotropic factor.
- “Cdh2” means Cadherin-2.
- “Cebpb” means CCAAT/enhancer-binding protein beta.
- “Crem” means cyclic-AMP response element binding.
- “Egr1” means Early
Growth Response Protein 1. - “Gria 4” means Glutamate Receptor Ionotropic AMPA 4.
- “Grm5” means
Metabotropic Glutamate Receptor 5. - “
Mapk 1” means Mitogen-ActivatedProtein Kinase 1. - “Nr4a1” means Nuclear Receptor Subfamily 4
Group A member 1, also known as Nerve Growth Factor IB. - “Ntf3” means Neurotrophin 3.
- “Ntf4” means Neurotrophin 4.
- “Pcdh8” means Protocadherin-8.
- “Plm1” means
Pre-mRNA Leakage Protein 1. - “Ppp3ca” means Protein Phosphatase 3, Catalytic Subunit, Alpha.
- “Tnf” means Tumor Necrosis Factor.
- PTHS means Pitt Hopkins Syndrome.
- “cG-2-AllylP,” “cyclic Glycyl-2-AllylP,” “NNZ2591,” and “NNZ-2591” each mean (8aS)-Allyl-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione.
- “Cyclic cyclohexyl-G-2-MeP” means (8aS)-Methyl-spiro[cyclohexane-1,3(4H)-tetrahydropyrrolo[1,2-a]pyrazine]-1,4(2H)-dione.
- “Cyclic cyclopentyl-G-2-MeP” means (8aS)-Methyl-spiro[cyclopentane-1,3(4H)-tetrahydropyrrolo[1,2-a]pyrazine]-1,4(2H)-dione.
- “tcf4” and “TCF4” refer to a gene implicated in PTHS.
- “tcf4+/− means the heterozygous mutation of the TCF4 gene associate with PTHS.
- Tcf4+/+ means wild-type TCF4.
- Impairment of the structure and function of synapses is a fundamental feature of PTHS. TCF4 is a transcription factor which regulates neurogenesis and neuronal migration in the brain. In humans, loss of function of the TCF4 gene leads to the rare neurodevelopmental disorder, PTHS, which is characterized by intellectual disability, developmental delay, and autistic behaviour. TCF4 is highly expressed during embryonic and early postnatal development (de Pontual et al, 2009) and has particularly high expression in the hippocampus (Brzózka et al, 2010; Sepp et al, 2011; Navarrete et al, 2013). It is also expressed in adult brain, lymphocytes, fibroblasts, gut, muscle, and myenteric plexus (Pscherer et al, 1996; Amiel et al, 2007; Brockschmidt et al, 2007; de Pontual et al, 2009). Recent cognitive and imaging studies have also shown that TCF4 is important for normal brain function (Blake et al, 2010; Navarrete et al, 2013).
- Deletions and mutations of the TCF4 gene disrupt the corresponding protein's ability to control the downstream activity of genes related to nervous system development and function (Sweatt, 2013). In particular, investigations have shown that TCF4 interacts with a potentially large repertoire of transcription factors including the products of proneural genes such as ASCL1, ATOH1, and NEUROD1 to regulate neurogenesis, cell differentiation, cell signaling, and survival in the developing brain (Flora et al, 2007; Blake et al, 2010; Brzózka et al, 2010; Bertrand et al, 2002; Forrest et al, 2013).
- Crux et al's, (2018) work on the consequences of functional loss of TCF4 on dendritic spines in mature neurons showed, with both homo- and heterozygous loss of TCF4, a reduction in the number of dendritic spines and changes in their morphology. This work suggested that TCF4 plays an important role in synaptic plasticity in mature neurons, independent of its developmental function, and functional loss of TCF4 may contribute to the neurological symptoms in PTHS.
- Changes in TCF4 also appear to alter gene expression of components of the IGF signaling pathways, in particular the down-regulation of genes encoding IGF binding proteins 3, 4, and 5 (Forrest et al, 2013). Cyclic Glycine-Proline has been reported to regulate binding of IGF-1 to IGF binding protein 3 in the brain and, as a consequence, regulate the bioavailability of IGF-1 (Guan et al, 2014). This auto-regulatory mechanism maintains homeostasis of IGF-1, increasing bioavailability when IGF-1 is deficient and decreasing bioavailability when IGF-1 levels are excessive. Both cGP and cG-2-AllylP also inhibit neuroinflammation which is part of the pathology underlying PTHS and contributes to over-activation of microglia which is critical for synaptic development and maintenance. Across numerous animal models of neurodevelopmental disorders, cG-2-AllylP normalizes the microglial phenotype which helps to restore synaptic function and morphology.
- Pitt Hopkins Syndrome can be assessed using one or more clinical tests, for example, Aberrant Behavior Checklist Community Edition (ABC), Aberrant Behavior Checklist (Stereotypy), Vinelands, Clinical Global Impression of Severity (CGI-S), the Caregiver Strain Questionnaire (CSQ), Children's Yale-Brown OC Scale (CYBOCS-PDD), Child Autism Rating Scale, Interview of Repetitive Behaviors, Nisonger Child Behavior Rating Scale, Pervasive Developmental Disorder Behavior Inventory, Stereotyped Behavior Scale, Repetitive Behavior Scale, Rossago Scale, Repetitive Behavior Questionnaire, PedQL™ Measurement Model, and Stereotyped Behavior Scale, or one or more physiological test selected from the group consisting of electroencephalogram (EEG) spike frequency, overall power in frequency bands of an EEG, hand movement, QTc and heart rate variability (HRV), and respiratory irregularities compared to control animals not suffering from said disorder.
- Anxiety can be assessed using one or more measures including, Anxiety, Depression and Mood Scale (ADAMS), Child and Adolescent Symptom Inventory (CASI), Child Behavior Checklist (CBCL), Multidimensional Anxiety Scale for Children (MASC), Pediatric Autism Rating Scale (PARS), Revised Child Anxiety and Depression Scale (RCAD), Screen for Child Anxiety Related Disorders (SCARED). Nisonger Child Behavior Rating Form, and Anxiety Diagnostic Interview Scale (ADIS).
- Social communication can be assessed using clinical tools, for example, ABAS-II Domain scores, Aberrant Behavior Checklist (ABC)-Lethargy/Social Withdrawal, ADI-R, Autism Diagnostic Observation Scale-Generic (ADOS-G)-new severity scores, Autism Impact Measure, Autism Spectrum Rating Scales, Autism Treatment Evaluation Checklist (ATEC), Ball Toss Game, Behavior Assessment Scale (BAS), Behavior Assessment System for Children 2nd Edition BASC-2 (subscales relevant to social), Behavior Rating Inventory of Executive Function, California Verbal Learning Task-Children's Version (VLT-C) and Modified VLT-C(MVLT-C), Caregiver-Child Interaction, Jahromi 2009, CGI, Childhood Autism Rating Scale (CARS), Children's Social Behavior Questionnaire, Clinical Evaluation of Language Fundamentals (CELF-3 and 4)-Pragmatics Profile, Communication and Symbolic Behavior Scales (CSBS), Comprehension of Affective Speech Task, General Trust Scale, Gilliam Autism Rating Scale (GARS), Joint Attention Measure from the ESCS (JAMES), Let's Face It!, Observational Assessment of Spontaneous Expressive Language (OSEL), Parent Questionnaire, Nagaraj et al. 2006, Parent's Rating Questionnaire, Chan et al, 2009, Pervasive Developmental Disorder Behavior Inventory (PDD-BI) (Short version available: PDD-BI-Screening Version), Reading the Mind in Films-Adult, Reading the Mind in Films-Child, Reading the Mind in the Eyes Task-Revised (RMET-R)-Adult, Reading the Mind in the Eyes Task-Revised (RMET-R)-Child, Reading the Mind in Voice-Adult, Social Communication Questionnaire (SCQ), Social Responsiveness Scale, Social Skills Improvement System (SSiS), Theory of Mind Test, and VABS-Socialization and Communication.
- Certain embodiments of this disclosure include derivatives of cyclic Glycyl Proline (“cGP”) having structures as described below.
- In certain embodiments, compounds of
Formula 1 include substituents where: - X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6; with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and; when R1═H, at least one of R2 and R3≠H.
- In further embodiments, compounds of
Formula 1 include substituents where: - R1=methyl, R2═R3═R4═R5═H, X1═NH, X2═CH2;
- R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2;
- R1═R2═R3═H, R4═R5=methyl, X1═NH, X2═CH2;
- R1═R4═R5═H, R2═R3=methyl, X1═NH, X2═CH2.
- In other embodiments of the invention, compounds of
Formula 1 include substituents where; - R4 and R5 taken together are —CH2—(CH2)n—CH2— and:
- R1=methyl, R2═R3═H, n=0, X1═NH, X2═CH2;
- R1=methyl, R2═R3═H, n=2, X1═NH, X2═CH2;
- R1=allyl, R2═R3═H, n=0, X1═NH, X2═CH2;
- R1=allyl, R2═R3═H, n=2, X1═NH, X2═CH2.
- R1=methyl, R2═R3═H, n=3, X1═NH, X2═CH2;
- R1=allyl, R2═R3═H, n=3, X1═NH, X2═CH2.
- In still other embodiments of the disclosure, compounds of
Formula 1 include substituents where R1=methyl or allyl, R2═R3═R4═H and R5 is selected from the group consisting of the side chains of the amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, proline, serine, threonine, tryptophan, tyrosine, valine, norvaline, norleucine, citruline, ornithine, homocysteine, homoserine, alloisoleucine, isovaline, sarcosine and the like. - In yet further embodiments of the invention, compounds of
Formula 1 include substituents where: - R1=methyl, R2═R3=methyl, R4═R5═H, X1═NH and X2═S;
- R1=allyl, R2═R3=methyl, R4═R5═H, X1═NH, and X2═S.
- Those with skill in the art will appreciate that the above structural representations can contain chiral centres, the number of which will depend on the different substituents. The chirality may be either R or S at each center. The structural drawings can represent only one of the possible tautomeric, conformational diastereomeric or enantiomeric forms, and it should be understood that the invention encompasses any tautomeric, conformational isomeric diastereomeric or enantiomeric form, which exhibits biological or pharmacological activity as described herein.
- Cyclic Glycyl-2-Allyl Proline (cG-2-AllylP) is described in U.S. Utility application Ser. No. 11/399,974 filed Apr. 7, 2006, entitled “Cyclic G-2Allyl Proline in Treatment of Parkinson's Disease,” now U.S. Pat. No. 7,776,876, issued Aug. 17, 2010, U.S. Utility application Ser. No. 10/570,395, filed Mar. 2, 2006 entitled “Neuroprotective Bicyclic Compounds and Methods for Their Use,” now U.S. Pat. No. 8,067,425, PCT International Patent Application No: PCT/US2004/028308, entitled “Neuroprotective Bicyclic Compounds and Methods for Their Use,” U.S. Provisional Patent Application Ser. No. 60/499,956 filed Sep. 3, 2003, entitled “Neuroprotective Bicyclic Compounds and Methods for Their Use,” and U.S. patent application Ser. No. 13/043,215 filed Mar. 8, 2011, entitled “Cyclic Glycyl-2-AllylProline Improves Cognitive Performance in Impaired Animals.” Each of the above patent applications and patents is expressly incorporated herein fully by reference.
- Other agents can be administered along with a compound of this invention. Such other agents may be selected from the group consisting of for example, growth factors and associated derivatives, e.g., insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), the tripeptide GPE, transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, and/or IGF-binding proteins.
- Compositions and methods of the invention find use in the treatment of animals, such as human patients, suffering from cognitive impairment and symptoms associated with Pitt Hopkins Syndrome. Still more generally, the compositions and methods of the disclosure find use in the treatment of mammals, such as human patients, suffering from memory impairment, intellectual disability, impaired social interaction, impairments in language and communication, impaired motor function, restricted and repetitive interests and behaviours, abnormal sleep behaviors, other aberrant behaviors and seizures.
- cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP, and related cyclic piperidines can be administered as part of a medicament or pharmaceutical preparation. This can involve combining a compound of the invention with any pharmaceutically appropriate carrier, adjuvant or excipient. The selection of the carrier, adjuvant or excipient will of course usually be dependent upon the route of administration to be employed.
- In general, compounds of this disclosure will be administered in therapeutically effective amounts by any of the usual modes known in the art, either singly or in combination with other conventional therapeutic agents for the disease being treated. A therapeutically effective amount may vary widely depending on the disease, its severity, the age and relative health of the animal being treated, the potency of the compound(s), and other factors. Therapeutically effective amounts of cyclic G-2-AllylP may range from 0.001 to 600 milligrams per kilogram mass of the animal, being appropriate for administration by methods such as oral, systemic (e.g. transdermal), scarification, or parenteral (e.g. intravenous) administration. A person of ordinary skill in the art will be able without undue experimentation, having regard to that skill and this disclosure, to determine a therapeutically effective amount of a compound.
- cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines and other cGP related compounds may be administered peripherally via any peripheral route known in the art. These can include parenteral routes for example injection into the peripheral circulation, subcutaneous, intraorbital, ophthalmic, intraspinal, intracisternal, topical, infusion (using e.g. slow release devices or minipumps such as osmotic pumps or skin patches), implant, aerosol, inhalation, scarification, intraperitoneal, intracapsular, intramuscular, intranasal, oral, buccal, transdermal, pulmonary, rectal or vaginal. The compositions can be formulated for parenteral administration to humans or other mammals in therapeutically effective amounts (e.g. amounts which eliminate or reduce the patient's pathological condition) to provide therapy for the neurological diseases described above.
- Desirably, cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines can be administered orally in an aqueous solution.
- Other convenient administration routes include subcutaneous injection (e.g. dissolved in a physiologically compatible carrier such as 0.9% sodium chloride)
- By “directly or indirectly via the circulation,” we mean administration of cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP or related cyclic piperidines to any tissue that has blood flow sufficient to deliver the agent into the circulation. Non-limiting examples include the skin, nose, pharynx, gastrointestinal tract, or other such tissue. When administered to such a tissue, the agent is absorbed by the tissue, where the agent enters the interstitial fluid of the tissue, and subsequently is absorbed by venules, capillaries, arterioles or lymph ducts. The agent is then carried into the general systemic circulation, where it can be delivered to the affected site, including the brain. When the agent is administered subcutaneously or peritoneally, the agent is absorbed by an adjacent tissue, and the agent then enters the circulation locally, and subsequently is delivered to the general circulation, where it can be transported to the brain. When the agent approaches the blood-brain barrier, the agent then can diffuse into the brain, either to neural tissue, or into the cerebrospinal fluid, where it can be delivered to neural tissues.
- The effective amount of compound in the CNS may be increased by administration of a pro-drug form of a compound, which comprises a compound of the invention and a carrier, where the carrier is joined to a compound of the invention by a linkage which is susceptible to cleavage or digestion within the patient. Any suitable linkage can be employed which will be cleaved or digested following administration.
- However, there is no intention on the part of the applicants to exclude other forms of administration.
- In further embodiments of the disclosure, restoring neurological function in an animal can comprise administering a therapeutic amount of cyclic G-2-AllylP in combination with another agent, selected from, for example, growth factors and associated derivatives (insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGF-binding proteins, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3 and FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10, FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 (BMP-2), glial-cell line derived neurotrophic factor, activity-dependent neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, interleukin), α-interferon, β-interferon, γ-interferon, or consensus interferon, and TNF-α. Other forms of therapeutic agents include, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, andrenocorticotropin-(4-9) analog (ORG 2766), dizolcipine (MK-801), selegiline; glutamate antagonists, NPS1506, GV1505260, MK-801, GV150526; AMPA antagonists, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070, LY300164, anti-inflammatory agents directed against the addressin MAdCAM-1 and/or its integrin α4 receptors (α4β1 and α4β7), anti-MAdCAM-1mAb MECA-367 (ATCC accession no. HB-9478).
- cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines and other cGP related compounds are suitably administered by a sustained-release system. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919; EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., 1983, Biopolymers: 22: 547-56), poly(2-hydroxyethyl methacrylate) (Langer et al., 1981, J. Biomed. Mater. Res.: 15: 267), ethylene vinyl acetate (Langer et al., 1981, J. Biomed. Mater. Res.: 15: 267), or poly-D-(−)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include a liposomally entrapped compound. Liposomes containing the compound are prepared by methods known per se: DE 3,218,121, EP 52,322, EP 36,676, EP 88,046, EP 143,949, EP 142,641, Japanese Pat. Appln. 83-118008, U.S. Pat. Nos. 4,485,045 and 4,544,545, and EP 102,324. Ordinarily, the liposomes are of the small (from or about 200 to 800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol percent cholesterol, the selected proportion being adjusted for the most efficacious therapy.
- For parenteral administration, in one embodiment cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines can be formulated generally by mixing each at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically, or parenterally, acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
- For delivery of a compound of this invention to a mucosal tissue, one can incorporate the compound into a gel formulation. Once delivered to the mucosa (e.g., oral cavity, gastrointestinal tract, rectum), the agent can diffuse out of the gel, or the gel can be degraded, thereby releasing the agent into the tissue, where it can be absorbed into the circulation. Exemplary gel formulations can include those made with carboxypolysaccharides such as carboxymethyl cellulose, carboxyethyl cellulose, chitin, chitosan, starch, cellulose, proteins such as hyaluronic acid, or other polymers, such as polyvinylpyrollidine, polyvinyl alcohols, as well as other gel materials known in the art
- Generally, the formulations are prepared by contacting cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, a buffered solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein.
- A carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; glycine; amino acids such as glutamic acid, aspartic acid, histidine, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose, trehalose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counter-ions such as sodium; non-ionic surfactants such as polysorbates, poloxamers, or polyethylene glycol (PEG); and/or neutral salts, e.g., NaCl, KCl, MgCl2, CaCl2, etc.
- cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines and other cGP compounds typically formulated in such vehicles at a pH of from or about 4.5 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of salts of the compound. The final preparation may be a stable liquid or lyophilized solid.
- Formulations of cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines in pharmaceutical compositions can also include adjuvants. Typical adjuvants which may be incorporated into tablets, capsules, and the like are a binder such as acacia, corn starch, or gelatin; an excipient such as microcrystalline cellulose; a disintegrating agent like corn starch or alginic acid; a lubricant such as magnesium stearate; a sweetening agent such as sucrose or lactose; a flavouring agent such as peppermint, wintergreen, or cherry. When dosage forms are tablets, cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidine compositions can include binders and optionally, a smooth coating. When the dosage form is a capsule, in addition to the above materials, it may also contain a liquid carrier such as a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. A syrup or elixir may contain the active compound, a sweetener such as sucrose, preservatives like propyl paraben, a colouring agent, and a flavouring agent such as cherry. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as water or naturally occurring vegetable oil like sesame, peanut, or cottonseed oil or a synthetic fatty vehicle like ethyl oleate or the like may be desired. Buffers, preservatives, antioxidants, and the like can be incorporated according to accepted pharmaceutical practice.
- A pharmaceutical formulation containing cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines ordinarily will be stored in unit or multi-dose containers, for example, in sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10 mL vials are filled with 5 mL of sterile-filtered 1% (w/v) aqueous solution of compound, and the resulting mixture is lyophilized. The solution is prepared by reconstituting the lyophilized compound using bacteriostatic Water-for-Injection. It can be readily appreciated that other dosage forms and types of preparations can be used, and all are considered to be part of this disclosure.
- Starting materials and reagents used in preparing cG-2-AllylP, cyclic cyclohexyl-G-2-MeP, cyclic cyclopentyl-G-2-MeP and/or related cyclic piperidines are either available from commercial suppliers such as Aldrich Chemical Company (Milwaukee, Wis.), Bachem (Torrance, Calif.), Sigma (St. Louis, Mo.), or are prepared by methods well known to the person of ordinary skill in the art following procedures described in such references as Fieser and Fieser's Reagents for Organic Synthesis, vols 1-17, John Wiley and Sons, New York, N.Y., 1991; Rodd's Chemistry of Carbon Compounds, vols. 1-5 and supplements, Elsevier Science Publishers, 1989; Organic Reactions, vols. 1-40, John Wiley and Sons, New York, N.Y., 1991; March J; Advanced Organic Chemistry, 4th ed. John Wiley and Sons, New York, N.Y., 1992; and Larock: Comprehensive Organic Transformations, VCH Publishers, 1989. In most instances, amino acids and their esters or amides, and protected amino acids, are widely commercially available; and the preparation of modified amino acids and their amides or esters are extensively described in the chemical and biochemical literature and thus well-known to persons of ordinary skill in the art.
- Starting materials, intermediates, and final products this disclosure may be isolated and purified using conventional techniques, including filtration, distillation, crystallization, chromatography, and the like. They may be characterized using conventional methods, including physical constants and spectral data.
- Cyclic G-2-AllylP is a cyclic dipeptide (bicyclic 2,5-diketopiperazine), and is a member of the class of compounds known as cyclic GPs (“cGP”). In general, cGPs and cyclic G-2-AllylP may be prepared by methods such as are already well-known to persons of ordinary skill in the art of peptide and modified peptide synthesis, following the reaction schemes set forth herein, or by following other methods well-known to those of ordinary skill in the art of the synthesis of peptides and analogues. See for example, Bodanzsky: Principles of Peptide Synthesis, Berlin, New York: Springer-Verlag 1993.
- Synthesis of the diketopiperazine compounds of this disclosure may be by solution-phase synthesis or via the solid-phase synthesis method exemplified by Merrifield et al. 1963 J. Amer. Chem. Soc.: 85, 2149-2156. Solid phase synthesis may be performed using commercial peptide synthesizers, such as the Applied Biosystems Model 430A, using the protocols established for the instrument.
- Specific examples of diketopiperazine synthesis can be found in Fischer, 2003, J. Peptide Science: 9: 9-35 and references therein. A person of ordinary skill in the art will have no difficulty, taking account of that skill and the knowledge available, and of this disclosure, in developing one or more suitable synthetic methods for compounds of this invention.
- The choice of appropriate protecting groups for the method chosen (solid-phase or solution-phase), and of appropriate substrates if solid-phase synthesis is used, will be within the skill of a person of ordinary skill in the art. Appropriate protecting groups for peptide synthesis include t-butyloxycarbonyl (Boc), fluorenylmethyloxycarbonyl (Fmoc), Benzyl (Bzl), t-amyloxycarbonyl (Aoc), tosyl (Tos), benzyloxycarbonyl (Z or Cbz), o-bromo-benzyloxycarbonyl (BrZ) and the like. Additional protecting groups are identified in Goodman M. (ed.), “Synthesis of Peptides and Peptidomimetics” in Methods of organic chemistry (Houben-Weyl) (Workbench Edition, E22a,b,c,d,e; 2004; Georg Thieme Verlag, Stuttgart, New York).
- The choice of coupling agent for the method chosen will also be within the skill of a person of ordinary skill in the art. Suitable coupling agents include DCC (N, N′-Dicyclohexylcarbodiimide), Bop (Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), PyBop (Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), BopCl (bis(2-oxo-3-oxazolidinyl)phosphinic chloride), 2-Chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP) and the like. Other compounds may be used in the synthesis e.g. to prevent racemisation, such as HOBt (N-Hydroxybenzotriazole) and HOAt (1-Hydroxy-7-azabenzotriazole).
- The specific embodiments presented below are not intended to be limiting to the scope of the invention. Persons of skill in the art can create other embodiments by incorporating one or more of the elements in the listing below into combinations not specifically set forth herein. All such embodiments are considered to be within the scope of the invention.
- Embodiment 1. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound having the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and;
- when R1═H, at least one of R2 and R3≠H.
- Embodiment 2. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound has the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2 and R3 are independently selected from the group consisting of group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- with the proviso that at least one R≠H.
- Embodiment 3. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound has the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2 and R3 are independently selected from the group consisting of group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6.
- Embodiment 4. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound of the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1, X3, and X4 are independently selected from the group consisting of S, O, and NH;
- X2 is selected from the group consisting of S, O, CH2 and NH;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- with the proviso that at least one R≠H and that both X3 and X4≠O.
- Embodiment 5. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound of the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- R1 and R2 are independently selected from the group consisting of group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R1 and R2 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6.
- Embodiment 6. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound of the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- R1, R2 and R3 are independently selected from the group consisting of group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6.
- Embodiment 7. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a compound of the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- R is selected from the group consisting of alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl.
- Embodiment 8. The method of any of
embodiments 1 to 4 or 6 where R1=methyl. - Embodiment 9. The method of any of
embodiments 1 to 4 or 6 where R1=allyl. - Embodiment 10. The method of any of
embodiments 1 to 4 where R2═R3=methyl and X2═S. - Embodiment 11. The method of
embodiment 1 where R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2. - Embodiment 12. The method of
embodiment 1 where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)3—CH2—, X1═NH, X2═CH2. - Embodiment 13. The method of
embodiment 1 where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)2—CH2—, X1═NH, X2═CH2. - Embodiment 14. The method of any of
embodiments 1 to 13, further comprising administering a pharmaceutically acceptable excipient. - Embodiment 15. The method of any of
embodiments 1 to 13, further comprising administering a pharmaceutically acceptable excipient and a binder. - Embodiment 16. The method of any of
embodiments 1 to 13, further comprising administering a pharmaceutically acceptable excipient and a capsule. - Embodiment 17. The method of any of
embodiments 1 to 13, further comprising administering at least one other anti-apoptotic, anti-necrotic or neuroprotective agent. - Embodiment 18. The method of embodiment 17 where the neuroprotective agent is selected from selected from growth factors and associated derivatives (insulin-like growth factor-I [IGF-I], insulin-like growth factor-II [IGF-II], transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGF-binding proteins, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3 and FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10 and FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 [BMP-2], glial-cell line derived neurotrophic factor, activity-dependent neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α-interferon, β-interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue [ORG 2766], dizolcipine [MK-801], selegiline, a glutamate antagonist, an AMPA antagonist, and an anti-inflammatory agent.
- Embodiment 19. The method of embodiment 18 wherein said glutamate and/or NMDA antagonist is selected from the group consisting of NPS1506, GV1505260, MK-801, and GV150526.
-
Embodiment 20. The method of embodiment 18 wherein said AMPA antagonist is selected from the group consisting of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070 and LY300164. - Embodiment 21. The method of embodiment 18, wherein said anti-inflammatory agent is selected from the group consisting of an anti-MAdCAM-1 antibody and an antibody against an integrin α4β1 receptor and an integrin α4β7 receptor.
- Embodiment 22. The method of embodiment 21 wherein said anti-MAdCAM-1 antibody is MECA-367.
- Embodiment 23. The method of
embodiment 1, wherein said compound is cyclic G-2-AllylP. - Embodiment 24. The method of
embodiment 1, wherein said compound is cyclic cyclohexyl-G-2MeP. - Embodiment 25. The method of
embodiment 1, wherein said compound is cyclic cyclopentyl-G-2MeP. - Embodiment 26. A method for treating a symptom of PTHS in an animal suffering from such a disorder, comprising administering to the animal, a pharmaceutically effective amount of cyclic Glycyl-2-Allyl Proline (cG-2-AllylP) to said mammal.
- Embodiment 27. The method of embodiment 26, wherein said cG-2-AllylP comprises an aqueous solution and one or more pharmaceutically acceptable excipients, additives, carriers or adjuvants.
- Embodiment 28. The method of embodiment 26, further comprising one or more excipients, carriers, additives, adjuvants or binders in a tablet or capsule.
- Embodiment 29. The method of any of
embodiments 1 to 30, where the compound is administered either directly or indirectly via the circulation. - Embodiment 30. The method of any of
embodiments 1 to 29, where said compound is administered via an oral, intraperitoneal, intravascular, peripheral circulation, subcutaneous, intraorbital, ophthalmic, intraspinal, intracisternal, topical, infusion, implant, aerosol, inhalation, scarification, intraperitoneal, intracapsular, intramuscular, intranasal, buccal, transdermal, pulmonary, rectal, or vaginal route. - Embodiment 31. The method of any of
embodiments 1 to 30, where said effective amount has a lower limit of about 0.001 milligrams per kilogram mass (mg/kg) of the animal and an upper limit of about 200 mg/kg. - Embodiment 32. The method of any of
embodiments 1 to 31, where assessment of efficacy is via measurement of phosphorylated ERK (pERK) or phosphorylated Akt (pAkt) in lymphocytes of the animal, where normalization of either pERK or pAkt indicates reduction in severity of said disorder. - Embodiment 33. The method of any of
embodiments 1 to 32, wherein said treatment produces an improvement in a symptom of PTHS as assessed using one or more clinical tests selected from the group consisting of the Aberrant Behavior Checklist Community Edition (ABC), Vineland Adaptive Behavior Scales, Clinical Global Impression of Severity (CGI-S), Clinical Global Impression Improvement (CGI-I), the Caregiver Strain Questionnaire (CSQ), or one or more physiological tests selected from the group consisting of electroencephalogram (EEG) spike frequency, overall power in frequency bands of an EEG, hemispheric coherence of EEG frequencies, stereotypic hand movement, QTc and heart rate variability (HRV), abnormal expression or activation of ERK1/2 and Akt, abnormal expression of growth-associated protein-43 (GAP-43), abnormal expression of synaptophysin (SYN), respiratory irregularities and coupling of cardiac and respiratory function compared to control animals not suffering from said disorder. - Embodiment 34. The method of any of embodiments 1-33, where said symptom of PTHS is cognitive impairment or cognitive dysfunction, one or more signs or symptoms of memory loss, loss of spatial orientation, decreased ability to learn, decreased ability to form short- or long-term memory, decreased episodic memory, decreased ability to consolidate memory, decreased spatial memory, decreased synaptogenesis, decreased synaptic stability, deficits in executive function, deficits in cognitive mapping and scene memory, deficits in declarative and relational memory, decreased rapid acquisition of configural or conjunctive associations, decreased context-specific encoding and retrieval of specific events, decreased episodic and/or episodic-like memory, anxiety, abnormal fear conditioning, abnormal social behaviour, repetitive behaviour, abnormal nocturnal behavior, seizure activity, abnormal locomotion, abnormal expression or activation of ERK1/2 and Akt, and bradycardia.
- Embodiment 35. A method for detecting presence of, severity, or evaluation of therapeutic efficacy of any of the preceding embodiments, comprising measuring expression of Phospho-ERK1/2 or Phospho-Akt in a peripheral lymphocyte of a subject with PTHS compared to the expression of Phospho-ERK1/2 or Phospho-Akt in a peripheral lymphocyte of a group of subjects not having PTHS, or to the expression Phospho-ERK1/2 or Phospho-Akt in a peripheral lymphocyte of the subject before treatment.
- Embodiment 36. Use of a compound in the manufacture of a medicament to treat a symptom of Pitt-Hopkins Syndrome, said compound being a pharmaceutically effective amount of a compound comprising cyclic Glycyl-2-Allyl Proline (cG-2-AllylP), cyclic cyclohexyl-G-2MeP, or cyclic cyclopentyl-G-2MeP.
- Embodiment 37. The use of Embodiment 36, wherein said compound is cyclic cyclohexyl-G-2MeP.
- Embodiment 38. The use of Embodiment 36, wherein said compound is cyclic G-2-allylP.
- Embodiment 39. The use of Embodiment 36, wherein said compound is cyclic cyclopentyl-G-2MeP.
- Embodiment 40. Use of a compound in the manufacture of a medicament for treating a symptom of Pitt Hopkins Syndrome in a mammal suffering from such a disorder, wherein said compound has the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and;
- when R1═H, at least one of R2 and R3≠H.
- Embodiment 41. The use of
Embodiment 40, where R1=methyl. - Embodiment 42. The use of
Embodiment 40, where R1=allyl. - Embodiment 43. The use of
Embodiment 40, where R2═R3=methyl and X2═S. - Embodiment 44. The use of
Embodiment 40, where R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2. - Embodiment 45. The use of
Embodiment 40, where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)3—CH2—, X1═NH, X2═CH2. - Embodiment 46. The use of
Embodiment 40, where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)2—CH2—, X1═NH, X2═CH2. - Embodiment 47. The use of any of
Claims 40 to 46, where the use further comprises said compound in a pharmaceutically acceptable excipient, or in a gel. - Embodiment 48. The use of any of
Embodiments 40 to 47, where the use further comprises said compound with a pharmaceutically acceptable excipient and a binder. - Embodiment 49. The use of any of
Embodiments 40 to 48, where the use further comprises said compound with a pharmaceutically acceptable excipient, or in a capsule. -
Embodiment 50. The use of any ofEmbodiments 40 to 49, further comprising least one anti-apoptotic compound, anti-necrotic compound, neuroprotective agent or an anti-inflammatory agent. - Embodiment 51. The use of Embodiment 50 where the anti-apoptotic compound, anti-necrotic compound, or neuroprotective agent is selected from the group consisting of insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3, FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10, FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 (BMP-2), glial-cell line derived neurotrophic factor, activity-dependent neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α-interferon, β-interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue (ORG 2766), dizolcipine [MK-801], selegiline, NPS1506, GV1505260, MK-801, GV150526, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070, LY300164, and the anti-MAdCAM-1 antibody MECA-367.
- Embodiment 52. The use of any of
Embodiments 40 to 50, said compound being cyclic G-2-AllylP. - Embodiment 53. The use of any of
Embodiments 40 to 50, wherein said compound is cyclic cyclohexyl-G-2MeP. - Embodiment 54. The use of any of
Embodiments 40 to 53, wherein said compound is cyclic cyclopentyl-G-2MeP. - Embodiment 55. The use of
Embodiment 40, further comprising one or more excipients, carriers, additives, adjuvants or binders in a tablet. - Embodiment 56. The use of
Claim 40, further comprising a microemulsion, coarse emulsion, or liquid crystal in a capsule. - Embodiment 57. A method for treating a mammal having Pitt Hopkins Syndrome, comprising administering to the mammal, a compound having the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and;
- when R1═H, at least one of R2 and R3≠H.
- Embodiment 58. The method of Embodiment 57 where R1=methyl.
- Embodiment 59. The method of Embodiment 57 where R1=allyl.
-
Embodiment 60. The method of Embodiment 57 where R2═R3=methyl and X2═S. - Embodiment 61. The method of Embodiment 57 where R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2.
- Embodiment 62. The method of Embodiment 57 where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)3—CH2—, X1═NH, X2═CH2.
- Embodiment 63. The method of Embodiment 57 where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)2—CH2—, X1═NH, X2═CH2.
- Embodiment 64. The method of Claim 57, where the method further comprises administering said compound along with a pharmaceutically acceptable excipient, or in a gel.
- Embodiment 65. The method of Embodiment 57, where the method further comprises administering said compound along with a pharmaceutically acceptable excipient and a binder.
- Embodiment 66. The method of Embodiment 57, where the method further comprises administering said compound along with a pharmaceutically acceptable excipient, or in a capsule.
- Embodiment 67. The method of Embodiment 57, further comprising administering at least one anti-apoptotic compound, anti-necrotic compound, neuroprotective agent or an anti-inflammatory agent.
- Embodiment 68. The method of Embodiment 67 where the anti-apoptotic compound, anti-necrotic compound, or neuroprotective agent is selected from the group consisting of insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3, FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10, FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 (BMP-2), glial-cell line derived neurotrophic factor, activity-dependent neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α-interferon, β-interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue (ORG 2766), dizolcipine [MK-801], selegiline, NPS1506, GV1505260, MK-801, GV150526, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070, LY300164, and the anti-MAdCAM-1 antibody MECA-367.
- Embodiment 69. The method of Embodiment 57, wherein said compound is cG-2-AllylP.
- Embodiment 70. The method of Embodiment 57, wherein said compound is cyclic cyclohexyl-G-2MeP.
- Embodiment 71. The method of Embodiment 57, wherein said compound is cyclic cyclopentyl-G-2MeP.
- Embodiment 72. A composition to treat a symptom of Pitt-Hopkins Syndrome, said composition comprising a pharmaceutically effective amount of a compound comprising cyclic Glycyl-2-Allyl Proline (cG-2-AllylP), cyclic cyclohexyl-G-2MeP, or cyclic cyclopentyl-G-2MeP.
- Embodiment 73. The composition of Embodiment 72, wherein said compound is cyclic cyclohexyl-G-2MeP.
- Embodiment 74. The composition of Embodiment 72, wherein said compound is cyclic G-2-allylP.
- Embodiment 75. The composition of Embodiment 72, wherein said compound is cyclic cyclopentyl-G-2MeP.
- Embodiment 76. A composition for treating a symptom of Pitt Hopkins Syndrome in a mammal suffering from such a disorder, comprising a compound having the formula:
- or a pharmaceutically acceptable salt or hydrate thereof, wherein
- X1 is selected from the group consisting of NR′, O and S;
- X2 is selected from the group consisting of CH2, NR′, O and S;
- R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
- or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
- with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and;
- when R1═H, at least one of R2 and R3≠H.
- Embodiment 77. The composition of Embodiment 76, where R1=methyl.
- Embodiment 78. The composition of Embodiment 76, where R1=allyl.
- Embodiment 79. The composition of Embodiment 76, where R2═R3=methyl and X2═S.
- Embodiment 80. The composition of Embodiment 76, where R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2.
- Embodiment 81. The composition of Embodiment 76, where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)3—CH2—, X1═NH, X2═CH2.
- Embodiment 82. The composition of Embodiment 76, where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)2—CH2—, X1═NH, X2═CH2.
- Embodiment 83. The composition of any of Embodiments 76 to 82, further comprising said compound in a pharmaceutically acceptable excipient, or in a gel.
- Embodiment 84. The composition of any of Embodiments 76 to 83, further comprising said compound with a pharmaceutically acceptable excipient and a binder.
- Embodiment 85. The composition of any of Embodiments 76 to 84, where the use further comprises said compound with a pharmaceutically acceptable excipient, or in a capsule.
- Embodiment 86. The composition of any of Embodiments 76 to 85, further comprising least one anti-apoptotic compound, anti-necrotic compound, neuroprotective agent or an anti-inflammatory agent.
- Embodiment 87. The composition of Embodiment 86 where the anti-apoptotic compound, anti-necrotic compound, or neuroprotective agent is selected from the group consisting of insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3, FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10, FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 (BMP-2), glial-cell line derived neurotrophic factor, activity-dependent neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α-interferon, β-interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue (ORG 2766), dizolcipine [MK-801], selegiline, NPS1506, GV1505260, MK-801, GV150526, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070, LY300164, and the anti-MAdCAM-1 antibody MECA-367.
- Embodiment 88. The composition of any of Embodiments 76 to 87, said compound being cyclic G-2-AllylP.
- Embodiment 89. The composition of any of Embodiments 76 to 87, wherein said compound is cyclic cyclohexyl-G-2MeP.
- Embodiment 90. The composition of any of Embodiments 76 to 87, wherein said compound is cyclic cyclopentyl-G-2MeP.
- Embodiment 91. The composition of Embodiment 76, further comprising one or more excipients, carriers, additives, adjuvants or binders in a tablet.
- Embodiment 92. The composition of Embodiment 76, further comprising a microemulsion, coarse emulsion, or liquid crystal in a capsule.
- Embodiment 93. The method of any of Claims 57 to 71, wherein said treatment produces an improvement in a symptom of PTHS as assessed using one or more clinical tests selected from the group consisting of the Aberrant Behavior Checklist Community Edition (ABC), Vineland Adaptive Behavior Scales, Clinical Global Impression of Severity (CGI-S), Clinical Global Impression Improvement (CGI-I), the Caregiver Strain Questionnaire (CSQ), or one or more physiological tests selected from the group consisting of electroencephalogram (EEG) spike frequency, overall power in frequency bands of an EEG, hemispheric coherence of EEG frequencies, stereotypic hand movement, QTc and heart rate variability (HRV), abnormal expression or activation of ERK1/2 and Akt, abnormal expression of growth-associated protein-43 (GAP-43), abnormal expression of synaptophysin (SYN), respiratory irregularities and coupling of cardiac and respiratory function compared to control animals not suffering from said disorder.
- Embodiment 94. The method of any of embodiments 57 to 71 or 93, where said symptom of PTHS is cognitive impairment or cognitive dysfunction, one or more signs or symptoms of memory loss, loss of spatial orientation, decreased ability to learn, decreased ability to form short- or long-term memory, decreased episodic memory, decreased ability to consolidate memory, decreased spatial memory, decreased synaptogenesis, decreased synaptic stability, deficits in executive function, deficits in cognitive mapping and scene memory, deficits in declarative and relational memory, decreased rapid acquisition of configural or conjunctive associations, decreased context-specific encoding and retrieval of specific events, decreased episodic and/or episodic-like memory, anxiety, abnormal fear conditioning, abnormal social behaviour, repetitive behaviour, abnormal nocturnal behavior, seizure activity, abnormal locomotion, abnormal expression or activation of ERK1/2 and Akt, and bradycardia.
- Embodiment 95. The method of any of
embodiments 1 to 71 or 93-94, where the dose of the compound is from about 0.001 mg/kg to about 600 mg/kg. - Embodiment 96. The composition of any of embodiments 72 to 92, wherein the amount of compound is sufficient to produce an administered dose of compound in the range of about 0.001 mg/kg to about 600 mg/kg.
- Embodiment 97. Any one or more of
Embodiments 1 to 96, where said animal or mammal is a human being. - The present disclosure is further illustrated by the following examples. These examples are offered by way of illustration only and are not intended to limit the scope of the invention.
- Flash chromatography was performed using Scharlau 60 (40-60 μm mesh) silica gel. Analytical thin layer chromatography was carried out on 0.20 mm pre-coated silica gel plates (ALUGRAM® SIL G/UV254) and compounds visualized using UV fluorescence, or heating of plates dipped in potassium permanganate in alkaline solution.
- Melting points in degrees Celsius (° C.) were determined on an Electrothermal® melting point apparatus and are uncorrected.
- Optical rotations were measured at 20° C. on a Perkin Elmer 341 polarimeter using 10 cm path length cells and are given in units of 10−1degcm2g−1. Samples were prepared in the solvent indicated at the concentration specified (measured in g/100 cm3). IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer. The samples were prepared as thin films on sodium chloride discs or as solids in potassium bromide discs. A broad signal indicated by br. The frequencies (ν) as absorption maxima are given in wavenumbers (cm−1).
- NMR spectra were recorded on a Bruker AVANCE DRX400 (1H, 400 MHz; 13C, 100 MHz) or a Bruker AVANCE 300 (1H, 300 MHz; 13C, 75 MHz) spectrometer at ambient temperatures. For 1H NMR data chemical shifts are described in parts per million downfield from SiMe4 and are reported consecutively as position (δH), relative integral, multiplicity (s=singlet, d=doublet, t=triplet, dd=doublet of doublets, m=multiplet, br=broad), coupling constant (J/Hz) and assignment. For 13C NMR data, chemical shifts are described in parts per million relative to CDCl3 and are reported consecutively as position (δC), degree of hybridization as determined by DEPT experiments, and assignment. 1H NMR spectra were referenced internally using SiMe4 (δ 0.00) or CDCl3 (δ 7.26). 13C NMR spectra were referenced internally using CDCl3 (δ 77.0). When two sets of peaks arise in the NMR spectra due to different conformations around the glycine-proline amide bond, the chemical shift for the minor cis conformer is marked with an asterisk (*).
- Accurate mass measurements were recorded on a VG-70SE mass spectrometer.
- Hexane and dichloromethane were distilled prior to use. Methanol was dried using magnesium turnings and iodine, and distilled under nitrogen. Triethylamine was dried over calcium hydride and distilled under nitrogen.
-
- n-BuLi (1.31 M, 4.68 cm3, 6.14 mmol) was added dropwise to a stirred solution of diisopropylamine (0.86 cm3, 6.14 mmol) in dry tetrahydrofuran (10 cm3) at −78° C. under an atmosphere of nitrogen. The solution was stirred for 5 min, warmed to 0° C. and stirred for 15 min. The solution was then added dropwise to a solution of oxazolidinone 8 (1.00 g, 4.09 mmol) in dry tetrahydrofuran (20 cm3) at −78° C. over 20 min (turned to a dark brown colour), stirred for a further 30 min then iodomethane (0.76 cm3, 12.3 mmol) was added dropwise over 5 min. The solution was warmed to −50° C. over 2 h. Water (15 cm3) was added and the solution warmed to room temperature and extracted with chloroform (3×40 cm3). The combined organic extracts were dried (MgSO4), filtered and evaporated to dryness in vacuo to give a dark brown semi-solid. Purification of the residue by flash column chromatography (15% ethyl acetate-hexane) afforded oxazolidinone 9 (0.67 g, 63%) as a pale yellow solid: mp 55-57° C. (lit., 57-60° C.); δH (300 MHz, CDCl3) 1.53 (3H, s, CH3), 1.72-2.02 (3H, m, Proβ-H and Proγ-H2), 2.18-2.26 (1H, m, Proβ-H), 3.15-3.22 (1H, m, Proδ-H), 3.35-3.44 (1H, m, Proδ-H) and 4.99 (1H, s, NCH).
- a) Using Acetyl Chloride
- Oxazolidinone 9 (0.60 g, 2.33 mmol) was dissolved in dry methanol (15 cm3) under an atmosphere of nitrogen and acetyl chloride (0.33 cm3, 4.66 mmol) was added dropwise to the ice-cooled solution. The solution was heated under reflux for 4.5 h, then the solvent removed under reduced pressure to give a brown oil which was purified by flash column chromatography (10% CH3OH—CH2Cl2) affording the hydrochloride 10 (0.2 g, 48%) as a flaky white solid: mp 107-109° C. (lit., 106-108° C.); δH (300 MHz, CDCl3) 1.81 (3H, s, CH3), 1.93-2.14 (3H, m, Proβ-HAHB and Proγ-H2), 2.33-2.39 (1H, m, Proβ-HAHB), 3.52-3.56 (2H, m, Proδ-H2) and 3.82 (3H, s, CO2CH3).
- b) Using Thionyl Chloride
- An ice-cooled solution of oxazolidinone 9 (53 mg, 0.21 mmol) in dry methanol (1 cm3) was treated dropwise with thionyl chloride (0.045 cm3, 0.62 mmol). The solution was heated under reflux for 2.5 h, cooled and the solvent removed under reduced pressure to yield a brown oil. The oil was dissolved in toluene (5 cm3), concentrated to dryness to remove residual thionyl chloride and methanol then purified by flash column chromatography (10% CH3OH—CH2Cl2) to afford the hydrochloride 10 (16 mg, 43%) as a flaky white solid. The 1H NMR assignments were in agreement with those reported above.
- Dry triethylamine (0.27 cm3, 1.96 mmol) was added dropwise to a solution of hydrochloride 10 (0.11 g, 0.61 mmol) and N-benzyloxycarbonyl-glycine 11 (98.5%) (0.17 g, 0.79 mmol) in dry dichloromethane (35 cm3) under an atmosphere of nitrogen at room temperature, and the reaction mixture stirred for 10 min. Bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BoPCl, 97%) (0.196 g, 0.77 mmol) was added and the resultant colourless solution was stirred for 20.5 h. The solution was washed successively with 10% aqueous hydrochloric acid (30 cm3) and saturated aqueous sodium hydrogen carbonate (30 cm3), dried (MgSO4), filtered and evaporated to dryness in vacuo. Purification of the resultant residue by flash column chromatography (50-80% ethyl acetate-hexane; gradient elution) yielded dipeptide 12 (0.18 g, 92%) as a colourless oil. Amide 12 was shown to exist as a 98:2 trans:cis mixture of conformers by 13C NMR analysis (the ratio was estimated from the relative intensities of the resonances at δ 20.8 and 23.5 assigned to the Proγ-C atoms of the minor and major conformers, respectively): [α]D-33.0 (c 1.0 in MeOH); νmax (film)/cm−1 3406, 2952, 1732, 1651, 1521, 1434, 1373, 1329, 1310, 1284, 1257, 1220, 1195, 1172, 1135, 1107, 1082, 1052, 1029, 986, 965, 907, 876, 829, 775, 738 and 699; δH (300 MHz, CDCl3) 1.49 (3H, s, CH3), 1.77-2.11 (4H, m, Proβ-H2 and Proγ-H2), 3.43-3.48 (2H, m, Proδ-H2), 3.61 (3H, s, OCH3), 3.85-3.89 (2H, m, Glyα-H2), 5.04 (2H, s, PhCH2), 5.76 (1H, br s, N—H) and 7.21-7.28 (5H, s, ArH); δC (75 MHz, CDCl3) 13.8* (CH3, Proα-CH3), 21.1 (CH3, Proα-CH3), 20.8* (CH2, Proγ-C), 23.5 (CH2, Proγ-C), 38.0 (CH2, Proβ-C), 40.8* (CH2, Proβ-C), 43.3 (CH2, Glyα-C), 45.5* (CH2, Glyα-C), 46.6 (CH2, Proδ-C), 48.7* (CH2, Proδ-C), 51.9* (CH3, OCH3), 52.1 (CH3, OCH3), 60.0* (quat., Proα-C), 66.0 (quat., Proα-C), 66.3 (CH2, PhCH2), 68.6* (CH2, PhCH2), 127.5 (CH, Ph), 127.6 (CH, Ph), 127.9* (CH, Ph), 128.1 (CH, Ph), 128.3* (CH, Ph), 136.2 (quat., Ph), 155.9 (quat., NCO2), 166.0 (quat., Gly-CON), 169.4* (quat., Gly-CON) and 173.6 (quat., CO2CH3); m/z (EI+) 334.1535 (M+. C17H22N2O5 requires 334.1529).
- To a solution of dipeptide 12 (0.167 g, 0.51 mmol) in methanol (8.0 cm3) was added 10% Pd on activated charcoal (8.1 mg, 0.076 mmol) and the vessel flushed with hydrogen gas. The resulting suspension was stirred vigorously under an atmosphere of hydrogen for 15 h. The mixture was then filtered through a Celite pad then a short plug of silica gel with methanol, and the solvent removed under reduced pressure to produce cyclic G-2MeP (83 mg, 98%) as a yellow solid: mp 133-135° C.; [α]D−128.1 (c 0.52 in MeOH); δH (300 MHz, CDCl3) 1.36 (3H, s, CH3), 1.87-2.01 (3H, m, Proβ-HAHB and Proγ-H2), 2.07-2.21 (1H, m, Proβ-HAHB), 3.45-3.64 (2H, m, Proδ-H2), 3.82 (1H, dd, J 17.1 and 4.1, CHAHBNH), 3.99 (1H, d, J 17.1, CHAHBNH) and 7.66 (1H, br s, N—H); δC (75 MHz, CDCl3) 20.2 (CH2, Proγ-C), 23.2 (CH3, Proα-CH3), 35.0 (CH2, Proβ-C), 44.7 (CH2, Proδ-C), 45.9 (CH2, CH2NH), 63.8 (quat., Proα-C), 163.3 (quat., NCO) and 173.3 (quat., CONH); m/z (EI+) 168.08986 (M+. C8H12N2O2 requires 168.08988).
-
- To a suspension of 1-aminocyclohexanecarboxylic acid 13 (0.72 g, 5.02 mmol) and sodium carbonate (1.6 g, 15.1 mmol) were dissolved in water-dioxane (21 cm3, 3:1) was added benzyl chloroformate (0.79 cm3, 5.52 mmol) was added dropwise and the solution was stirred at room temperature for 19.5 h. The aqueous layer was washed with diethyl ether (60 cm3), acidified with 2 M HCl and extracted with ethyl acetate (2×60 cm3). The organic layers were combined, dried (MgSO4), filtered and evaporated under reduced pressure to produce a colourless oil, which solidified on standing to crude carbamate 14 (1.23 g, 88%) as a white solid: mp 152-154° C. (lit., 148-150° C.); δH (400 MHz, CDCl3) 1.27-1.56 (3H, m, 3× cyclohexyl-H), 1.59-1.73 (3H, m, 3× cyclohexyl-H), 1.85-1.91 (2H, m, 2× cyclopentyl-H), 2.05-2.09 (2H, m, 2× cyclopentyl-H), 5.02 (1H, br s, N—H), 5.12 (2H, s, OCH2Ph) and 7.27-7.36 (5H, s, Ph); δC (100 MHz, CDCl3) 21.1 (CH2, 2× cyclohexyl-C), 25.1 (CH2, 2× cyclohexyl-C), 32.3 (CH2, cyclohexyl-C), 59.0 (quat.,1-C), 67.1 (CH2, OCH2Ph), 128.1 (CH, Ph), 128.2 (CH, Ph), 128.5 (CH, Ph), 136.1 (quat., Ph), 155.7 (quat., NCO2) and 178.7 (quat., CO2H).
- Dry triethylamine (0.21 cm3, 1.5 mmol) was added dropwise to a solution of hydrochloride 10 (84.0 mg, 0.47 mmol), carboxylic acid 14 (0.17 g, 0.61 mmol) and 1-hydroxy-7-azabenzotriazole (16 mg, 0.12 mmol) in dry 1,2-dichloroethane (26 cm3) under an atmosphere of nitrogen at room temperature, and the reaction mixture stirred for 10 min. 2-Chloro-1,3-dimethylimidazolidinium hexafluorophosphate (0.13 g, 0.47 mmol) was added and the resultant solution heated under reflux for 21 h, then washed successively with 10% aqueous hydrochloric acid (30 cm3) and saturated aqueous sodium hydrogen carbonate (30 cm3), dried (MgSO4), filtered and evaporated to dryness in vacuo. Purification of the resultant residue by flash column chromatography (40-50% ethyl acetate-hexane; gradient elution) yielded amide 15 (16 mg, 9%) as a white solid. Amide 15 was shown to exist as a 11:1 trans:cis mixture of conformers by 13C NMR analysis (the ratio was estimated from the relative intensities of the resonances at δ 41.3 and 48.2 assigned to the Proδ-C atoms of the minor and major conformers, respectively): mp 219-222° C.; [α]D−44.9 (c 1.31 in CH2Cl2); νmax (film)/cm−1 3239, 2927, 1736, 1707, 1617, 1530, 1450, 1403, 1371, 1281, 1241, 1208, 1194, 1165, 1150, 1132, 1089, 1071, 1028, 984, 912, 796, 749, 739 and 699; δH (400 MHz, CDCl3) 1.24-2.10 (17H, m, Proα-CH3, Proβ-H2, Proγ-H2 and 5× cyclohexyl-H2), 3.25-3.48 (1H, br m, Proδ-HAHB), 3.61-3.87 (4H, br m, OCH3 and Proδ-HAHB), 4.92-5.19 (3H, m, N—H and OCH2Ph) and 7.35-7.37 (5H, s, Ph); &(100 MHz, CDCl3) 21.26 (CH2, cyclohexyl-C), 21.33 (CH2, cyclohexyl-C), 21.7 (CH3, Proα-CH3), 24.8 (CH2, cyclohexyl-C), 25.0 (CH2, Proγ-C), 29.4* (CH2, cyclohexyl-C), 29.7* (CH2, cyclohexyl-C), 31.1 (CH2, cyclohexyl-C), 31.6 (CH2, cyclohexyl-C), 31.9* (CH2, cyclohexyl-C), 32.2* (CH2, cyclohexyl-C), 32.8* (CH2, cyclohexyl-C), 37.3 (CH2, Proβ-C), 41.4* (CH2, Proδ-C), 48.2 (CH2, Proδ-C), 52.1 (CH3, OCH3), 59.1 (quat., Glyα-C), 66.7 (CH2, OCH2Ph), 67.3* (CH2, OCH2Ph), 67.4 (quat., Proα-C), 128.0* (CH, Ph), 128.1* (CH, Ph), 128.3 (CH, Ph), 128.5 (CH, Ph), 128.7 (CH, Ph), 136.6 (quat., Ph), 153.7 (quat., NCO2), 171.0 (quat., Gly-CO) and 174.8 (quat., CO2CH3); m/z (EI+) 402.2151 (M+. C22H30N2O5 requires 402.2155).
- To a solution of amide 15 (40 mg, 0.01 mmol) in methanol (3.3 cm3) was added 10% Pd on activated charcoal (1.6 mg, 0.015 mmol) and the vessel flushed with hydrogen gas. The resulting suspension was stirred vigorously under an atmosphere of hydrogen for 61.5 h, then filtered through a Celite™ pad with methanol (15 cm3). The filtrate was concentrated to dryness under reduced pressure to produce a yellow semi-solid which was purified by reverse-phase C18 flash column chromatography (0-10% CH3CN/H2O; gradient elution) to produce cyclic cyclohexyl-G-2MeP (19 mg, 81%) as a white solid: mp 174-177° C.; [α]D −63.8 (c 1.13 in CH2Cl2); νmax (film)/cm1 3215, 2925, 2854, 1667, 1646, 1463, 1427, 1276, 1232, 1171, 1085, 1014, 900, 868, 818, 783, 726 and 715; δH (400 MHz, CDCl3) 1.31-1.89 (12H, m, 9× cyclohexyl-H and 8a-CH3), 1.94-2.15 (4H, m, 7-H2 and 8-H2), 2.26 (1H, td, J 13.7 and 4.5, 1× cyclohexyl-H), 3.44-3.51 (1H, m, 6-HAHB), 3.79-3.86 (1H, m, 6-HAHB) and 6.40 (1H, br s, N—H); δC (100 MHz, CDCl3) 19.5 (CH2, 7-C), 20.6 (CH2, cyclohexyl-C), 20.8 (CH2, cyclohexyl-C), 24.5 (CH2, cyclohexyl-C), 25.0 (CH3, 8a-CH3), 33.7 (CH2, cyclohexyl-C), 36.3 (CH2, 8-C), 36.5 (CH2, cyclohexyl-C), 44.7 (CH2, 6-C), 59.5 (quat., 8a-C), 64.0 (quat., 3-C), 168.1 (quat., 4-C) and 171.6 (quat., 1-C); m/z (EI+) 236.15246 (M+. C13H20N2O2 requires 236.15248).
-
- n-BuLi (1.31 M, 9.93 cm3, 13.0 mmol) was added dropwise to a stirred solution of diisopropylamine (1.82 cm3, 13.0 mmol) in dry tetrahydrofuran (20 cm3) at −78° C. under an atmosphere of nitrogen. The solution was stirred for 5 min, warmed to 0° C., stirred for 15 min then added dropwise to a solution of pro-oxazolidinone 16 (2.12 g, 8.68 mmol) in dry tetrahydrofuran (40 cm3) at −78° C. over 20 min and the reaction mixture was stirred for a further 30 min then allyl bromide (2.25 cm3, 26.0 mmol) was added dropwise over 5 min. The solution was warmed slowly to −30° C. over 4 h, quenched with H2O (30 cm3) and the mixture warmed to room temperature and extracted with chloroform (3×80 cm3). The combined organic extracts were dried (MgSO4), filtered and evaporated to dryness in vacuo to produce a dark brown semi-solid which was purified by flash column chromatography (10-20% ethyl acetate-hexane; gradient elution) to produce oxazolidinone 17 (1.48 g, 60%) as an orange oil which solidified at 0° C., for which the nmr data were in agreement with that reported in the literature: δH (400 MHz, CDCl3) 1.58-1.92 (2H, m, Proγ-H2), 1.96-2.14 (2H, m, Proβ-H2), 2.50-2.63 (2H, m, Pro-H2), 3.12-3.23 (2H, m, CH2—CH═CH2), 4.97 (1H, s, NCH), 5.13-5.18 (2H, m, CH═CH2) and 5.82-5.92 (1H, m, CH═CH2); δC (100 MHz, CDCl3) 25.1 (CH2, Proγ-C), 35.1 (CH2, Proβ-C), 41.5 (CH2, Proδ-C), 58.3 (CH2, CH2CH═CH2), 71.2 (quat., Proα-C), 100.4 (quat., CCl3), 102.3 (CH, NCH), 119.8 (CH2, CH2CH═CH2), 131.9 (CH, CH2CH═CH2) and 176.1 (quat., C═O); m/z (CI+) 284.0009 [(M+H)+. C10H13 35Cl3NO2 requires 284.0012], 285.9980 [(M+H)+. C10H13 35Cl2 37ClNO2 requires 285.9982], 287.9951 [(M+H)+. C10H13 35Cl2 37Cl2NO2 requires 287.9953] and 289.9932 [(M+H)+. C10H13 37Cl3NO2 requires 289.9923].
- An ice-cooled solution of oxazolidinone 17 (0.64 g, 2.24 mmol) in dry methanol (15 cm3) was treated dropwise with a solution of acetyl chloride (0.36 cm3, 5.0 mmol) in methanol (5 cm3). The solution was heated under reflux for 24 h, then cooled and the solvent removed under reduced pressure. The resultant brown oil was dissolved in toluene (40 cm3) and concentrated to dryness to remove residual thionyl chloride and methanol, then purified by flash column chromatography (5-10% CH3OH—CH2Cl2; gradient elution) to afford hydrochloride 18 (0.29 g, 63%) as a green solid for which the NMR data were in agreement with that reported in the literature: δH (300 MHz, CDCl3) 1.72-2.25 (3H, m, Proβ-HAHB and Proγ-H2), 2.32-2.52 (1H, m, Proβ-HAHB), 2.72-3.10 (2H, m, Proδ-H2), 3.31-3.78 (2H, m, CH2CH═CH2), 3.84 (3H, s, CO2CH3), 5.20-5.33 (2H, m, CH═CH2), 5.75-5.98 (1H, m, CH═CH2) and 8.06 (1H, br s, N—H); m/z (CI+) 170.1183 [(M+H)+. C9H16NO2 requires 170.1181].
- Dry triethylamine (0.28 cm3, 2.02 mmol) was added dropwise to a solution of hydrochloride 18 (0.13 g, 0.63 mmol) and N-tert-butyloxycarbonyl-glycine 19 (0.14 g, 0.82 mmol) in dry dichloromethane (35 cm3) under an atmosphere of nitrogen at room temperature, and the reaction mixture was stirred for 10 min. Bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BoPCl, 97%) (0.20 g, 0.80 mmol) was added and the solution stirred for 19.5 h, then washed successively with 10% aqueous hydrochloric acid (35 cm3) and saturated aqueous sodium hydrogen carbonate (35 cm3), dried (MgSO4), filtered and evaporated to dryness in vacuo. Purification of the resultant residue by flash column chromatography (40% ethyl acetate-hexane) yielded dipeptide 20 (0.09 g, 45%) as a light yellow oil: [α]D+33.8 (c 0.83 in CH2Cl2); νmax (film)/cm−1 3419, 3075, 2977, 2930, 2874, 1739, 1715, 1656, 1499, 1434, 1392, 1366, 1332, 1268, 1248, 1212, 1168, 1122, 1051, 1026, 1003, 943, 919, 867, 830, 779, 739, 699 and 679; δH (300 MHz, CDCl3) 1.42 [9H, s, C(CH3)3], 1.93-2.08 (4H, m, Proβ-H2 and Proγ-H2), 2.59-2.67 (1H, m, CHAHBCH═CH2), 3.09-3.16 (1H, m, CHAHBCH═CH2), 3.35-3.44 (1H, m, Proδ-HAHB), 3.56-3.62 (1H, m, Proδ-HAHB), 3.70 (3H, s, OCH3), 3.89 (2H, d, J 4.2, Glyα-H2), 5.06-5.11 (2H, m, CH═CH2), 5.42 (1H, br s, Gly-NH) and 5.58-5.72 (1H, m, CH═CH2); δC (75 MHz, CDCl3) 23.7 (CH2, Proγ-C), 28.3 [CH3, C(CH3)3], 35.0 (CH2, Proβ-C), 37.6 (CH2, CH2CH═CH2), 43.3 (CH2, Glyα-C), 47.5 (CH2, Proδ-C), 52.5 (CH3, OCH3), 68.8 (quat., Proα-C), 79.5 [quat., C(CH3)3], 119.4 (CH2, CH═CH2), 132.9 (CH, CH═CH2), 155.7 (quat., NCO2), 166.9 (quat., Gly-CON) and 173.8 (quat., CO2CH3); m/z (EI+) 326.1845 (M+. C16H26N2O5 requires 326.1842).
- To a solution of dipeptide 20 (0.09 g, 0.28 mmol) in dichloromethane (9 cm3) at room temperature was added trifluoroacetic acid (1 cm3, 0.013 mmol) dropwise and the reaction mixture was stirred for 1 h under an atmosphere of nitrogen. The solution was evaporated under reduced pressure to give a colorless oil which was dissolved in dichloromethane (10 cm3), dry triethylamine (0.096 cm3, 0.69 mmol) was added and the reaction mixture stirred for 4.5 h, after which further triethylamine (0.096 cm3, 0.69 mmol) was added. The reaction mixture was stirred overnight, concentrated to dryness to give a green oil which was purified by flash column chromatography (10% CH3OH—CH2Cl2) to produce cyclic G-2AllylP (20 mg, 37%) as an off-white solid: mp 106-109° C.; [α]D−102.7 (c 0.95 in CH2Cl2); νmax (CH2Cl2)/cm−1 3456, 3226, 2920, 1666, 1454, 1325, 1306, 1299, 1210, 1133, 1109, 1028, 1010, 949, 928, 882, 793, 761 and 733; δH (400 MHz, CDCl3) 1.92-2.01 (2H, m, Proγ-H2), 2.09-2.16 (2H, m, Proβ-H2), 2.39-2.56 (2H, m, CH2CH2═CH2), 3.46-3.53 (1H, m, Proδ-HAHB), 3.78-3.87 (2H, m, Proδ-HAHB and Glyα-HAHB), 4.09 (1H, d, J 17.2, Glyα-HAHB), 5.16-5.20 (2H, m, CH═CH2), 5.73-5.84 (1H, m, CH═CH2) and 7.17 (1H, br s, N—H); δC (100 MHz, CDCl3) 20.1 (CH2, Proγ-C), 34.1 (CH2, Proβ-C), 41.7 (CH2, CH2CH2═CH2), 44.9 (CH2, Pro-C), 46.4 (CH2, Glyα-C), 67.2 (quat., Proα-C), 120.9 (CH2, CH═CH2), 131.0 (CH, CH═CH2), 163.4 (quat., NCO) and 171.7 (quat., CONH); m/z (EI+) 195.1132 (M+. C10H15N2O2 requires 195.1134).
-
- A solution of benzyl chloroformate (0.290 g, 1.1 mmol) in dioxane (2.5 cm3) was added dropwise to a solution of 1-aminocyclopentanecarboxylic acid (Fluka) (0.2 g, 1.54 mmol) and sodium carbonate (0.490 g, 4.64 mmol) in water (5 cm3) at 0° C. Stirring was continued at room temperature overnight and the reaction mixture washed with ether. The aqueous layer was acidified with 2M hydrochloric acid, extracted with ethyl acetate, dried (Na2SO4), filtered and the solvent removed to afford carbamate 21 (0.253 g, 62%) as an oil which solidified on standing. Carbamate 21 was shown to be a 70:30 mixture of conformers by 1H NMR analysis (the ratio was estimated from the integration of the resonances at δ 5.31 and 7.29-7.40, assigned to the N—H protons of the major and minor conformers, respectively): mp 70-80° C. (lit.1 82-86° C., ethyl acetate, petroleum ether); δH (400 MHz; CDCl3; Me4Si) 1.83 (4H, br s, 2× cyclopentyl-H2), 2.04 (2H, br s, cyclopentyl-H2), 2.20-2.40 (2H, m, cyclopentyl-H2), 5.13 (2H, br s, OCH2Ph), 5.31 (0.7H, br s, N—H) and 7.29-7.40 (5.3H, m, Ph and N—H*); δC (100 MHz; CDCl3) 24.6 (CH2, cyclopentyl-C), 37.5 (CH2, cyclopentyl-C), 66.0 (quat., cyclopentyl-C), 66.8 (CH2, OCH2Ph), 128.0 (CH, Ph), 128.1 (CH, Ph), 128.4 (CH, Ph), 136.1 (quat, Ph), 155.8 (quat., NCO2) and 179.5 (quat., CO2H). * denotes resonance assigned to minor conformer.
- Dry triethylamine (0.19 cm3, 1.4 mmol) was added dropwise to a solution of hydrochloride 10 (78 mg, 0.43 mmol), carboxylic acid 21 (0.15 g, 0.56 mmol) and 1-hydroxy-7-azabenzotriazole (Acros) (15 mg, 0.11 mmol) in dry 1,2-dichloroethane (24 cm3) under an atmosphere of nitrogen at room temperature, and the reaction mixture stirred for 10 min. 2-Chloro-1,3-dimethylimidazolidinium hexafluorophosphate (CIP) (Aldrich) (0.12 g, 0.43 mmol) was added and the resultant solution heated under reflux for 19 h, then washed successively with 10% aqueous hydrochloric acid (30 cm3) and saturated aqueous sodium hydrogen carbonate (30 cm3), dried (MgSO4), filtered and evaporated to dryness in vacuo. Purification of the resultant residue by flash column chromatography (60% ethyl acetate-hexane) yielded amide 22 (39 mg, 23%) as a white solid. Amide 22 was shown to exist as a 3:1 trans:cis mixture of carbamate conformers by 13C NMR analysis (the ratio was estimated from the relative intensities of the resonances at δ 154.1 and 155.7 assigned to the carbamate carbonyl-C atoms of the major and minor conformers, respectively): mp 200-203° C.; [α]D −54.5 (c 1.52 in CH2Cl2); νmax (film)/cm−1 3432, 3239, 3042, 2953, 1736, 1712, 1627, 1540, 1455, 1417, 1439, 1374, 1282, 1256, 1216, 1194, 1171, 1156, 1136, 1100, 1081, 1042, 1020, 107, 953, 917, 876, 756 and 701; δH (400 MHz, CDCl3) 1.33-1.53 (3H, br m, Proα-CH3), 1.62-2.20 (11H, m, Proβ-H2, Proγ-H2 and 7× cyclopentyl-H), 2.59-2.71 (1H, br m, 1× cyclopentyl-H), 3.31-3.42 (1H, br m, Proδ-HAHB), 3.58-3.79 (4H, br m, OCH3 and Proδ-HAHB), 4.92-5.17 (3H, m, N—H and OCH2Ph) and 7.27-7.42 (5H, s, Ph); δC (100 MHz, CDCl3) 21.7 (CH3, Proα-CH3), 24.1* (CH2, cyclopentyl-C), 24.2 (CH2, cyclopentyl-C), 24.4 (CH2, Proγ-C), 24.5 (CH2, cyclopentyl-C), 36.4 (CH2, cyclopentyl-C), 37.1 (CH2, cyclopentyl-C), 37.2* (CH2, cyclopentyl-C), 37.7 (CH2, Proβ-C), 38.2* (CH2, cyclopentyl-C), 48.5 (CH2, Pro-C), 52.1 (CH3, OCH3), 66.6 (CH2, OCH2Ph), 66.9 (quat., Proα-C), 67.2 (quat., Glyα-C), 127.8 (CH, Ph), 128.2 (CH, Ph), 128.4 (CH, Ph), 136.6 (quat., Ph), 154.1 (quat., NCO2), 155.7* (quat., NCO2), 170.5 (quat., Gly-CO) and 174.7 (quat., CO2CH3); m/z (EI+) 388.1991 (M+. C21H28N2O5 requires 388.1998).
- To a solution of amide 22 (54 mg, 0.14 mmol) in methanol (4.6 cm3) was added 10% Pd on activated charcoal (2.2 mg, 0.021 mmol) and the vessel flushed with hydrogen gas. The resulting suspension was stirred vigorously under an atmosphere of hydrogen for 17 h, then filtered through a Celite™ pad with methanol (15 cm3). The filtrate was concentrated to dryness under reduced pressure to give a yellow semi-solid which was purified by reverse-phase C18 flash column chromatography (0-10% CH3CN/H2O; gradient elution) to afford cyclic cyclopentyl-G-2MeP (20 mg, 65%) as a yellow solid: mp 160-163° C.; [α]D −97.9 (c 1.61 in CH2Cl2); νmax (film)/cm−1 3429, 2956, 2928, 2856, 1667, 1643, 1463, 1432, 1373, 1339, 1254, 1224, 1175, 1086, 1048, 976, 835, 774 and 730; δH (300 MHz, CDCl3) 1.47 (3H, br s, 8a-CH3), 1.56-2.19 (11H, m, 8-H2, 7-H2 and 7× cyclopentyl), 2.58-2.67 (1H, br m, 1× cyclopentyl), 3.48-3.56 (1H, m, 6-HAHB), 3.72-3.82 (1H, m, 6-HAHB) and 6.56 (1H, br s, N—H); δC (75 MHz, CDCl3) 19.9 (CH2, 7-C), 24.6 (CH2, cyclopentyl), 24.92 (CH3, 8a-CH3), 24.93 (CH2, cyclopentyl), 36.0 (CH2, 8-C), 38.7 (CH2, cyclopentyl), 41.9 (CH2, cyclopentyl), 44.8 (CH2, 6-C), 64.3 (quat., 8a-C), 66.8 (quat., 3-C), 168.3 (quat., 4-C) and 172.2 (quat., 1-C); m/z (EI+) 222.1369 (M+. C12H18N2O2 requires 222.1368).
- The following pharmacological studies demonstrate efficacy of cyclic G-2-AllylP in attenuation of symptoms of PTHS. They are not intended to be limiting, and other compositions and methods of this invention can be developed without undue experimentation. All of those compositions and methods are considered to be part of this disclosure. All the following experiments were carried out using protocols developed under guidelines approved by the University of Chile Animal Ethics Committee or comparable regulatory bodies.
- In an in vivo study, male Sprague Dawley rats (aged 14 weeks) received a single dose of cG-2-AllylP, either 100 mg/kg or 200 mg/kg by oral gavage. Cerebrospinal fluid (CSF) and whole blood were collected at 1.5 and 4 hours postdose, and brain tissue was collected at 4 hours postdose to evaluate cG-2-AllylP exposure. Table 1 below shows the blood, CSF, and brain cG-2-AllylP in CSF and blood 1.5 hours after dosing.
-
Concentration of cG-2-AllylP in CSF, Blood and the Brain in Wild Type Rats Mean Test Article Exposure Dose 100 mg/ kg 200 mg/kg 200:100 mg/kg 1.5 h postdose CSF 40.4 μg/ml 82.2 μg/ml 2.03:1 Blood 58.5 μg/ml 116.0 μg/ml 1.98:1 4 h postdose CSF 11.0 μg/ml 24.7 μg/ml 2.25:1 Blood 15.6 μg/ml 34.2 μg/ml 2.19:1 Brain 22.6 μg/ml 37.0 μg/ml 1.63:1 CSF = cerebrospinal fluid. - There was an approximately proportional increase in the concentration of cG-2-AllylP in blood and CSF at 1.5 hours and in blood, CSF and brain at 4 hours following a single, oral dose. At 4 hours post dose, the concentration of cG-2-AllylP in blood and brain tissue was approximately equivalent.
- A. Relevance of Mouse Model
- Several genetically manipulated rodent models of PTHS have been created (Thaxton et al, 2018; Sweatt, 2013). These models share a common basis around heterozygous Tcf4 (Tcf4+/−). Haploinsufficient mice (Tcf4+/−) have been characterized as a model system for PTHS (Kennedy et al, 2016). Kennedy et al's (2016) work showed that Tcf4+/− mice demonstrate behavior consistent with the cognitive and motor dysregulation associated with PTHS, including aversion to social interaction, learning deficits, and impairments in gross motor control.
- B. Experimental Design
- In vivo behavioral studies were conducted in Tcf4+/− mutant and wildtype littermate control (WT) mice by Gen.DDI (Santiago, Chile). Littermate controls consist of the genotypes Tcf4+/+. All Tcf4 mutant mice used were heterozygous for the Tcf4 mutation because homozygous mutations of Tcf4 result in embryonic to
postnatal day 1 lethality. Ten mice per treatment group, 14 weeks of age, were used for behavioral experiments. Experiments were conducted in line with the requirements of the UK Animals (Scientific Procedures) Act, 1986. The mice were housed in plastic cages (35×30×12 cm), 5 in each and habituated to the animal facilities for at least a week before commencing the test. The room temperature (21° C.±2° C.), relative humidity (55%±5%), a 12-hour light-dark cycle (lights on 7 AM to 7 PM), and air exchange were automatically controlled. The animals had free access to commercial food pellets and water. Testing was performed during the light phase of the circadian cycle, with the order of testing being determined by the principle of conducting the most stressful tests last. Assays were designed to reproduce and expand on the original behavioral characterization of Tcf4+/− mice. Tcf4+/− and WT control mice were treated for 6 weeks prior to testing and tested 30 minutes following a dose of cG-2-AllylP, as described in Table 2 below. -
Dosing Regimens Group No. Testing Groups Oral Concentration Treatment N 1 WT + Vehicle o.p. BID, 30 min 10 prior to test 2 KO + Vehicle o.p. BID, 30 min 10 prior to test 3 WT + cG-2-AllylP o.p. 100 mg/kg BID, 30 min 10 prior to test 4 KO + cG-2-AllylP o.p. 100 mg/kg BID, 30 min 10 prior to test 5 WT + cG-2-AllylP o.p. 200 mg/kg BID, 30 min 10 prior to test 6 KO + cG-2-AllylP o.p. 200 mg/kg BID, 30 min 10 prior to test BID = twice a day dosing; KO = Knock Out; o.p. = per os; WT = wildtype littermate control. - The Open Field (OF) test is a combined test that is used to determine anxiety/hyperactivity, and for habituation to a novel environment, one of the most elementary forms of learning, in which decreased exploration as a function of repeated exposure to the same environment is taken as an index of memory. This is normally studied in two sessions of exposure to the open field, a 10-min and a 24 hr habituation session.
- The device used for this study is a grey PVC enclosed
arena 50×30 cm divided into 10 cm squares. Mice are brought to the experimental room 5-20 min before testing. A mouse is placed into a corner square facing the corner and observed for 3 min. The number of squares entered (whole body) and rears (both front paws off the ground, but not as part of grooming) are counted. The latency to the first rear is also noted. The movement of the mouse around the field was recorded with a video tracking device for 300 s (vNT4.0, Viewpoint). The latency for the mouse to enter the brightest, central part of the field total time spent in this central region, and total activity (in terms of path length in centimetres), were recorded. - The open field (OF) test is a test used to characterize explorative behavior, anxiety, and/or hypo- and hyperactivity in animals habituated to daily handling under novel and familiar conditions. During exposure to the open field mice will habituate to the environment and thus explore less, decreasing the amount movement they show over time.
- In the present experiment, we recorded movement and rearing during an initial exposure (T1), during a second exposure after 10 minutes (T2) and during a third exposure after 24 hours (T3). Failures to reduce locomotion or rearing at 10 minutes and 24 hours indicate deficits in short- and long-term memory, respectively.
- To evaluate whether cG-2-AllylP is effective to treat the hypoactivity in PTHS, we carried out Open Field studies. Lower scores on measures of open field locomotion were detected in Tcf4+/− as compared to WT littermates, across the 30-minute test session.
- The results are shown in
FIG. 2 . - The relative distance travelled is shown on the vertical axis, and the animals and their treatments are shown on the horizontal axis. Wild type (WT) mice treated with vehicle alone (left column) were considered to travel 100%. Tcf4+/− mice treated with vehicle alone (second column from left) exhibited only about 60% of the mobility compared to WT mice, and therefore were found to be hypoactive. WT mice treated with NNZ-2591 (cG-2-AllylP) (third from left column) exhibited slightly higher mobility than WT mice treated with vehicle, but this difference was small and not statistically significant. In contrast to the Tcf4+/− mice treated with vehicle alone, we surprisingly found that Tcf4+/− mice treated with 100 mg/kg NNZ-2591 (cG-2-AllylP); fourth column from left, showed nearly identical mobility as did WT mice treated with vehicle alone. WT mice treated with 200 mg/kg of NNZ-2591 (cG-2AllylP); fifth column from left) exhibited nearly the same mobility as did WT mice treated either with vehicle alone or with 100 mg/kg of NNZ-2591 (cG-2-AllylP). The effect of NNZ-2591 (cG-2-AllylP) were statistically significant. We conclude that NNZ-2591 (cG-2-AllylP) at either 100 mg/kg or 200 mg/kg normalized this mild to moderate hypoactivity in Tcf4+/− mice.
-
-
ANOVA Summary F 166.2 P value <.00001 P value summary **** Significant difference among means (P < 0.05)? Yes R square 0.939 Tukey’s Multiple Comparison Test Summary P Value WT + vehicle vs Tcf4+/− + vehicle **** <0.00001 WT + vehicle vs WT + cG-2-AllylP (100 mg/kg) ns 0.1546 WT + vehicle vs Tcf4+/− + cG-2-AllylP (100 ns >0.9999 mg/kg) WT + vehicle vs WT + cG-2-AllylP (200 mg/kg) ns 0.3821 WT + vehicle vs Tcf4+/− + cG-2-AllylP (200 ns 0.9782 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP 1 (200 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (200 **** <0.0001 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.1137 Tcf4+/− + cG-2-AllylP (100 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.9957 WT + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.5145 Tcf4+/− + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.3037 WT + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.9524 Tcf4+/− + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (200 mg/kg) vs ns 0.8203 Tcf4+/− + cG-2-AllylP (200 mg/kg) ANOVA = analysis of variance; ns = not significant; WT = wildtype littermate control; **** = p < 0.00001 - Repetitive self-grooming is a feature of mice. Tcf4+/− mice show an increased amount of self-grooming compared to wild type mice. To see if NNZ-2591 (cG-2-AllylP) can normalize self-grooming behavior in Tcf4+/− mice, we carried out a series of studies, as shown in
FIG. 3 . - The amount of time spent grooming in seconds during a 10-minute test period is shown on the vertical axis, and the animals and treatments are shown on the horizontal axis. Wild type (WT) mice treated with vehicle alone (left column) self-groomed for about 110 sec. Tcf4+/− mice treated with vehicle alone (second column from left) had an increase in self-grooming compared to WT mice treated with vehicle alone. WT mice treated with 100 mg/kg NNZ-2591 (cG-2-AllylP; third column from left) self-groomed for about the same amount of time as did WT mice treated with vehicle alone. This difference was not statistically significant. We unexptectedly found that Tcf4+/− mice treated with 100 mg/kg NNZ-2591 (cG-2-AllylP; fourth column from left) or 200 mg/kg (right column) spent about the same amount of time self-grooming as WT vehicle treated mice and less than the time spent self-grooming in Tcf4+/− mice treated with vehicle alone. This statistically significant finding was completely unexpected in Tcf4+/− mice.
-
-
ANOVA Summary F 53.01 P value <0.0001 P value summary **** Significant difference among means (P < 0.05)? Yes R square 0.8307 Tukey’s Multiple Comparison Test Summary P Value WT + vehicle vs Tcf4+/− + vehicle **** 0.0001 WT + vehicle vs WT + cG-2-AllylP (100 mg/kg) ns >0.9999 WT + vehicle vs Tcf4+/− + cG-2-AllylP (100 ns 0.0567 mg/kg) WT + vehicle vs WT + cG-2-AllylP (200 mg/kg) ns >0.9999 WT + vehicle vs Tcf4+/− + cG-2-AllylP (200 ns 0.9149 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (200 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (200 **** <0.0001 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.0645 Tcf4+/− + cG-2-AllylP (100 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns >0.9999 WT + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.9313 Tcf4+/− + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.0645 WT + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.4130 Tcf4+/− + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (200 mg/kg) vs ns 0.9313 Tcf4+/− + cG-2-AllylP (200 mg/kg) ANOVA = analysis of variance; ns = not significant; WT = wildtype littermate control **** = p < 0.0001 - We conclude that the elevation in a repetitive behavior (self grooming) as a consequence of the Tcf4+/− mutation was corrected by treatment with cG-2-AllylP at doses of either 100 mg/kg or 200 mg/kg.
- Fear conditioning to either an event or a context represents a form of associative learning that has been well studied in many species. In mice, fear is often shown as stopping movement, also known as freezing behavior. Freezing is adaptive for prey species because predators often locate moving prey. The dependent measure used in contextual (delay) fear conditioning is a freezing response that takes place following pairing of an unconditioned stimulus (foot shock), with a conditioned stimulus (CS; e.g., an audible tone), a particular context and/or such a cue. If in a conditioning context one administers a foot shock that is paired with a tone, there will be learning not only to the tone, but also to the context.
- Contextual fear conditioning is a basic conditioning procedure. It involves taking an animal and placing it in a novel environment, providing an aversive stimulus, and then removing it. When the animal is returned to the same environment, it generally will demonstrate a freezing response if it remembers and associates that environment with the aversive stimulus. Freezing is a response to fear, which has been defined as “absence of movement except for respiration.” This freezing behavior may last from seconds to minutes depending on the strength of the aversive stimulus, the number of presentations, and the degree of learning achieved by the subject.
- Animals with the Tcf4+/− mutation show less freezing behavior than wild type mice. This maladaptive behavior can have serious consequences. Therefore, to determine if NNZ-2591 (cG-2-AllylP) can restore normal fear conditioning in Tcf4+/− mice, we carried out a series of studies.
FIG. 4 shows the results of these studies. - The percent of time spent in freezing over a 5-minute test period is shown on the vertical axis of
FIG. 4 . Animals and their treatments are shown on the horizontal axis. - Wild type mice treated with vehicle alone (left column) spent about 50% of the time in freezing behavior. Tcf4+/− mice (second column from left), in contrast, showed a substantial reduction in the time spent in freezing behavior. This was statistically significant.
- WT mice treated with either 100 mg/kg (third column from left) or 200 mg/kg (fifth column from left) of NNZ-2591 (cG-2-AllylP) exhibited about the same amount of time in freezing behavior as did vehicle-treated WT mice.
- In contrast to vehicle-treated Tcf4+/− mice, mice treated with either 100 mg/kg (fourth column from left) or 200 mg/kg (right column) spent a similar time in freezing behavior as WT mice. The difference between WT and animals treated with 200 mg/kg was not statistically significantly. However, the amount of time spent in freezing behavior of the NNZ-2591 (cG-2-AllylP)-treated mice was substantial and statistically significantly higher than vehicle-treated Tcf4+/− mice.
-
-
ANOVA Summary F 169.4 P value <0.0001 P value summary **** Significant difference among means (P < 0.05)? Yes R square 0.9401 Tukey’s Multiple Comparisons Test Summary P Value WT + vehicle vs Tcf4+/− + vehicle **** <0.0001 WT + vehicle vs WT + cG-2-AllylP (100 mg/kg) ns 0.8232 WT + vehicle vs Tcf4+/− + cG-2-AllylP (100 * 0.0109 mg/kg) WT + vehicle vs WT + cG-2-AllylP (200 mg/kg) ns 0.6468 WT + vehicle vs Tcf4+/− + cG-2-AllylP (200 ns 0.9492 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (200 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (200 **** <0.0001 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.2139 Tcf4+/− + cG-2-AllylP (100 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.0811 WT + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs nx 0.2819 Tcf4+/− + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs **** <0.0001 WT + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs *** 0.0006 Tcf4+/− + cG-2-AllylP (200 mg/kg) WT+ cG-2-AllylP (200 mg/kg) vs Tcf4+/− + ns 0.9897 cG-2-AllylP (200 mg/kg) ANOVA = analysis of variance; ns = not significant; WT = wildtype littermate control; **** = p < 0.0001: *** = p < 0.001; * = p < 0.05 - Social recognition and social memory in humans are very important. People with PTHS show lower amounts of social recognition and memory compared with people without PTHS. Similarly, Tcf4+/− mice show substantially reduced social interaction compared to wild type mice. Therefore, to determine if NNZ-2591 (cG-2-AllylP) could be effective in normalizing this condition, we carried out a series of studies in mice, in which we determined the amount of time that mice spent sniffing a novel mouse.
- To carry out these studies, mice were evaluated by the amount of time spent sniffing a novel mouse upon repeated exposures, to induce familiarity, and reinstatement of high levels of sniffing when a novel stimulus animal is introduced. We measured the number of bouts of sniffing in each of the groups of animals. Results of these studies are shown in
FIG. 5 . The time spent sniffing a novel mouse is shown on the vertical axis and the animals and treatments are shown on the horizontal axis. - Time spent sniffing a novel mouse by WT mice treated with vehicle only (left column) was used as the control in the experiment. Tcf4+/− mice treated with vehicle only (second column from left) showed a substantially lower amount of time sniffing the novel mouse. WT mice treated with either 100 mg/kg (third column from left) or 200 mg/km (fifth column from left) showed nearly identical times spend sniffing the novel mouse. Tcf4+/− mice treated with cG-2-AlylP at doses of either 100 mg/kg (fourth column from left) or 200 mg/kg (right column) showed substantial and statistically significant increases in the amount of time spent with the novel mouse compared to Tcf4+/− mice treated with vehicle only.
-
-
Tukey’s Multiple Comparison Test Summary P Value WT + vehicle vs Tcf4+/− + vehicle **** <0.0001 WT + vehicle vs WT + cG-2-AllylP (100 mg/kg) ns >0.9999 WT + vehicle vs Tcf4+/− + cG-2-AllylP (100 mg/kg) ns 0.2590 WT + vehicle vs Tcf4+/− + cG-2-AllylP (200 mg/kg) ns 0.8811 Tcf4+/− + vehicle vs WT + cG-2-AllylP (100 mg/kg) **** <0.0001 Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (200 mg/kg) **** <0.0001 Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (200 **** <0.0001 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns >0.9999 Tcf4+/− + cG-2-AllylP (100 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.2321 WT + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.8553 Tcf4+/− + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.2590 WT + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-02-AllylP (100 mg/kg) vs ns 0.8811 Tcf4+/− + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (200 mg/kg) vs ns 0.8811 Tcf4+/− + cG-2-AllylP (200 mg/kg) ANOVA = analysis of variance; ns = not significant; WT = wildtype littermate control; **** = p < 0.0001 - Nest building is an activity needed for mice to raise their offspring and is an indicator of social adaptation and activities of daily living. Tcf4+/− mice build nests of substantially lower quality than wild type mice. Therefore, to determine if NNZ-2591 (cG-2-AllylP) might restore the quality of nest building, we carried out a series of studies. Results are shown in
FIG. 6 . The vertical axis shows nest building quality on a grade of 1-5, and the horizontal axis shows animals and treatments. - Wild type mice treated with vehicle only exhibited nest building quality of about 5. In contrast, Tcf4+/− mice treated with vehicle only (second column from left) built nexts of substantially lower quality. WT animals treated with either 100 mg/kg (NNZ-2591 (cG-2-AllylP; third column from left or 200 mg/kg (fifth column from left) built nests of quality nearly identical to those of vehicle-treated WT mice. Tcf4+/− mice treated with either 100 mg/kg (fourth column from left) or 200 mg/kg NNZ-2591 (cG-2-AllylP; right column) normalized the quality of nests to levels nearly identical to WT mice. The differences in quality of nests built by the Tcf4+/− mice treated with NNZ-2591 were substantially and statistically significantly better than those built by the Tcf4+/− mice treated with vehicle only.
-
-
ANOVA Summary F 121.9 P value <0.0001 P value summary **** Significant difference among means (P < 0.05)? Yes R square 0.9186 Tukey’s Multiple Comparison Test Summary P Value WT + vehicle vs Tcf4+/− + vehicle **** <0.0001 WT + vehicle vs WT + cG-2-AllylP (100 mg/kg) ns >0.9999 WT + vehicle vs Tcf4+/− + cG-2-AllylP (100 mg/kg) ns 0.9951 WT + vehicle vs WT + cG-2-AllylP (200 mg/kg) ns 0.9951 WT + vehicle vs Tcf4+/− + cG-2-AllylP (200 mg/kg) ns >0.9999 Tcf4+/− + vehicle vs WT + cG-2-AllylP (100 mg/kg) **** <0.0001 Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (200 mg/kg) **** <0.0001 Tcf4+/− + vehicle vs Tcf4+/−+ cG-2-AllylP (200 **** <0.0001 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0/9951 Tcf4+/− + cG-2-AllylP (100 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.9951 WT + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns >0.9999 Tcf4+/− + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns >0.9999 WT + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.9951 Tcf4+/− + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (200 mg/kg) vs ns 0.9951 Tcf4+/− + cG-2-AllylP (200 mg/kg) ANOVA = analysis of variance; no = not significant; WT = wildtype littermate control; **** = p < 0.0001. - Hind limb force is an important measure of the ability of a mouse to jump away from a predator. However, animals with the Tcf4+/− mutation have substantially lower ability to jump away from a predator, making this mutation very serious and potentially life threatening. Hind limb force is also considered a surrogate for motor function in humans. To determine if NNZ-2591 (cG-2-AllylP) might provide a helpful treatment for this condition, we carried out a series of studies in which we measured hind limb force. These results are shown in
FIG. 7 . The vertical axis shows the force in Newtons (N), and the horizontal axis shows the animals and treatments. - Wild type mice treated with vehicle only were able to generate about 8 N of force. In contrast, vehicle-treated Tcf4+/− mice (second column from left) were able to produce only about 0.3 N. This is a substantial and statistically significant deficit. WT mice treated with either 100 mg/kg NNZ-2591 (third column from left) or 200 mg/kg (fifth column from left) were able to generate about the same levels of force as vehicle-treated WT mice. Tcf4+/− mice treated with either 100 mg/kg (fourth column from left) or 200 mg/kg NNZ-2591 (right column) produced forces nearly identical to those produced by WT mice. In contrast, Tcf4+/− mice treated with either 100 mg/kg (fourth column from left) or 200 mg/kg NNZ-2591 were able to produce substantially and statistically significantly greater force than vehicle-treated Tcf4+/− mice. Therefore, we conclude that the weakness and motor dysfunction due to PTHS was normalized by treatment with cG-2-AllylP.
-
-
ANOVA summary F 28.14 P value <.0001 P value summary **** Significant difference among means (P < 0.05)? Yes R square 0.7226 Tukey’s Muliple Comparison Test Summary P Value WT + vehicle vs Tcf4+/− + vehicle **** <0.0001 WT + vehicle vs WT + cG-2-AllylP (100 mg/kg) ns 0.9490 WT + vehicle vs Tcf4+/− + cG-2-AllylP (100 mg/kg) ns 0.6371 WT + vehicle vs WT + cG-2-AllylP (200 mg/kg) ns 0.9853 WT + vehicle vs Tcf4+/− + cG-2-AllylP (200 mg/kg) ns 0.3631 Tcf4+/− + vehicle vs WT + cG-2-AllylP (100 mg/kg) **** <0.0001 Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (100 **** <0.0001 mg/kg) Tcf4+/− + vehicle vs WT + cG-2-AllylP (200 mg/kg) **** <0.0001 Tcf4+/− + vehicle vs Tcf4+/− + cG-2-AllylP (200 **** <0.0001 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.1649 Tcf4+/− + cG-2-AllylP (100 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.6371 WT + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (100 mg/kg) vs ns 0.0616 Tcf4+/− + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.9490 WT + cG-2-AllylP (200 mg/kg) Tcf4+/− + cG-2-AllylP (100 mg/kg) vs ns 0.9978 Tcf4+/− + cG-2-AllylP (200 mg/kg) WT + cG-2-AllylP (200 mg/kg) vs ns 0.7702 Tcf4+/− + cG-2-AllylP (200 mg/kg) ANOVA = analysis of variance; ns = not significant; WT = wildtype littermate control; **** = p <0.00001. - As summarized in Table 3, using the Tcf4+/− mouse model, treatment with cG-2-AllylP at 200 mg/kg for 6 weeks rescued all tested behaviors of the PTHS phenotype. At 100 mg/kg, treatment with cG-2-AllylP rescued all tested behaviors, except for fear conditioning, which was improved but remained significantly different to Wild Type.
-
TABLE 3 Summary of Behaviors Normalized to WildType Levels Open Self- Fear Field groom Con Nesting Sociability Force Tcƒ4+/− + cG-2-AllylP ✓ ✓ X ✓ ✓ ✓ (100 mg/kg) Tcƒ4+/− + cG-2-AllylP ✓ ✓ ✓ ✓ ✓ ✓ (200 mg/kg) - All patents and patent applications referred to, and the following references are incorporated herein fully by reference.
- Amiel J, Rio M, de Pontual L, et al. Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction. Am J Hum Genet. 2007; 80(5):988-993.
- Bertrand N, Castro D S, Guillemot F. Proneural genes and the specification of neural cell types. Nat Rev Neurosci. 2002; 3(7):517-530.
- Blake D J, Forrest M, Chapman R M, et al. TCF4, schizophrenia, and Pitt-Hopkins Syndrome. Schizophr Bull. 2010; 36(3):443-447. doi: https://doi. org/10. 1093/schbul/sbq035.
- Brockschmidt A, Todt U, Ryu S, et al. Severe mental retardation with breathing abnormalities (Pitt-Hopkins syndrome) is caused by haploinsufficiency of the neuronal bHLH transcription factor TCF4. Hum Mol Genet. 2007; 16(12):1488-1494.
- Brzozka M M, Radyushkin K, Wichert S P, Ehrenreich H, Rossner M J. Cognitive and Sensorimotor Gating Impairments in Transgenic Mice Overexpressing the Schizophrenia Susceptibility Gene Tcf4 in the Brain. Biol Psychiatry. 2010; 68(1):33-40. https://doi.org/10. 1016/j.biopsych. 2010. 03.015.
- Crux S, Herms J, Dorostkar M M. Tcf4 regulates dendritic spine density and morphology in the adult brain. PLoS ONE. 2018; 13(6):e0199359. https://doi. org/10.1371/journal. pone. 0199359.
- de Pontual L, Mathieu Y, Golzio C, et al. Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins Syndrome. Hum Mutat. 2009; 30(4):669-676.
- Flora A, Garcia J J, Thaller C, Zoghbi H Y. The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors. Proc Nat Acad Sci U.S.A. 2007; 104(39):15382-15387. DOI:10.1073/pnas.0707456104.
- Forrest M P, Waite A J, Martin-Rendon E, Blake D J. Knockdown of human TCF4 affects multiple signaling pathways involved in cell survival, epithelial to mesenchymal transition and neuronal differentiation. PLoS One. 2013; 8(8):e73169. https://doi.org/10.1371/journal.pone. 0073169.
- Guan J, Mathai S, Harris P, et al. Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacology. 2007; 53(6):749-762. https://doi.org/10.1016/j.neuropharm. 2007.08.010.
- Guan J, Zhang R, Dale-Gandar L, Hodgkinson S, Vickers M H. NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behav Brain Res. 2010; 210(2):221-228. https://doi.org/10.1016/j.bbr.2010.02.039
- Guan J, Gluckman P, Yang P et al. Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1. Sci Rep. 2014; 4:4388. DOI:10.1038/srep04388.
- Kennedy A J et al. Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Rep. 2016 Sep. 6; 16(10): 2666-2685. 10.1016/j.celrep.2016. 08.004.
- Krishnamurthi R V, Mathai S, Kim A H, Zhang R, Guan J. A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats. Br J Pharmacol. 2009; 156(4):662-672.
- Navarrete K, Pedroso I, De Jong S, et al. TCF4 (e2-2; ITF2): A schizophrenia-associated gene with pleiotropic effects on human disease. Am J Med Genet B Neuropsychiatr Genet. 2013; 162B(1):1-16. doi:https://doi.org/10.1002/ajmg.b. 32109.
- Pscherer A, Dorflinger U, Kirfel J, et al. The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene. EMBO J. 1996; 15(23):6680-6690. https://doi.org/10.1002/j.1460-2075. 1996. tb01058.x
- Rosenfeld J A, Leppig K, Ballif B C, et al. Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations. Genet Med. 2009; 11(11):797-805.
- Sepp M, Kanike K, Eesmaa A, Urb M, Timmusk T. Functional diversity of human basic helix-loop-helix transcription factor TCF4 isoforms generated by
alternative 5′ exon usage and splicing. PLoS One. 2011; 6(7):e22138. doi:10.1371/journal.pone.0022138. - Sweatt J D. Pitt-Hopkins Syndrome: intellectual disability due to loss of TCF4-regulated gene transcription. Exp Mol Med. 2013; 45:e21. doi:10.1038/emm.2013.32.
- Sweetser D A, Elsharkawi I, Yonker L, et al. Pitt-Hopkins Syndrome. 2012 Aug. 30 [Updated 2018 Apr. 12]. In: Adam M P, Ardinger H H, Pagon R A, et al., editors. Gene Reviews® [Internet]. Seattle (Wash.): University of Washington, Seattle; 1993-2019.
- Thaxton C, Kloth A D, Clark E P, Moy S S, Chitwood R A, Philpot B D. Common Pathophysiology in Multiple Mouse Models of Pitt-Hopkins Syndrome. J Neurosci. 2018; 24; 38(4):918-936. doi: 10.1523/JNEUROSCI.1305-17.2017. Epub 2017 Dec. 8.
- UK Animals (Scientific Procedures) Act, 1986.
- United States Census Bureau, Population Clock; July 12′ 2019; 0.045 UTC. www. census.gov/popclock.
- Embodiments of this disclosure are useful in the medical and veterinary arts and are industrially applicable.
Claims (21)
1. A method for treating a mammal having Pitt Hopkins Syndrome, comprising administering to the mammal, a compound having the formula:
or a pharmaceutically acceptable salt or hydrate thereof, wherein
X1 is selected from the group consisting of NR′, O and S;
X2 is selected from the group consisting of CH2, NR′, O and S;
R1, R2, R3, R4 and R5 are independently selected from the group consisting of —H, —OR′, —SR′, —NR′R′, —NO2, —CN, —C(O)R′, —C(O)OR′, —C(O)NR′R′, —C(NR′)NR′R′, trihalomethyl, halogen, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl and substituted heteroarylalkyl; each R′ is independently selected from the group consisting of —H, alkyl, heteroalkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl;
or R4 and R5 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
or R2 and R3 taken together are —CH2—(CH2)n—CH2— where n is an integer from 0-6;
with the proviso that when R1=methyl and R2═R3═R4═H then R5≠benzyl and;
when R1═H, at least one of R2 and R3≠H.
2. The method of claim 1 where R1=methyl.
3. The method of claim 1 where R1=allyl.
4. The method of claim 1 where R2═R3=methyl and X2═S.
5. The method of claim 1 where R1=allyl, R2═R3═R4═R5═H, X1═NH, X2═CH2.
6. The method of claim 1 where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)3—CH2—, X1═NH, X2═CH2.
7. The method of claim 1 where R1=methyl, R2═R3═H, R4 and R5 taken together are —CH2—(CH2)2—CH2—, X1═NH, X2═CH2.
8. The method of claim 1 , where the method further comprises administering said compound along with a pharmaceutically acceptable excipient, and/or in a gel.
9. The method of claim 1 , where the method further comprises administering said compound along with a pharmaceutically acceptable excipient and a binder.
10. The method of claim 1 , where the method further comprises administering said compound along with a pharmaceutically acceptable excipient, or in a capsule.
11. The method of claim 1 , further comprising administering at least one anti-apoptotic compound, anti-necrotic compound, neuroprotective agent or an anti-inflammatory agent.
12. The method of claim 11 where the anti-apoptotic compound, anti-necrotic compound, or neuroprotective agent is selected from the group consisting of insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II), transforming growth factor-β1, activin, growth hormone, nerve growth factor, growth hormone binding protein, IGFBP-3, basic fibroblast growth factor, acidic fibroblast growth factor, the hst/Kfgk gene product, FGF-3, FGF-4, FGF-6, keratinocyte growth factor, androgen-induced growth factor, int-2, fibroblast growth factor homologous factor-1 (FHF-1), FHF-2, FHF-3, FHF-4, keratinocyte growth factor 2, glial-activating factor, FGF-10, FGF-16, ciliary neurotrophic factor, brain derived growth factor, neurotrophin 3, neurotrophin 4, bone morphogenetic protein 2 (BMP-2), glial-cell line derived neurotrophic factor, activity-dependent neurotrophic factor, cytokine leukaemia inhibiting factor, oncostatin M, an interleukin, α-interferon, β-interferon, γ-interferon, consensus interferon, TNF-α, clomethiazole; kynurenic acid, Semax, tacrolimus, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, adrenocorticotropin-(4-9) analogue (ORG 2766), dizolcipine [MK-801], selegiline, NPS1506, GV1505260, MK-801, GV150526, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX), LY303070, LY300164, and the anti-MAdCAM-1 antibody MECA-367.
13. The method of claim 1 , wherein said compound is cG-2-AllylP.
14. The method of claim 1 , wherein said compound is cyclic cyclohexyl-G-2MeP.
15. The method of claim 1 , wherein said compound is cyclic cyclopentyl-G-2MeP.
16. The method of claim 1 , wherein said treatment produces an improvement in a symptom of the disorder as assessed using one or more clinical tests selected from the group consisting of Aberrant Behavior Checklist Community Edition (ABC), Vineland Adaptive Behavior Scales, Clinical Global Impression of Severity (CGI-S), Clinical Global Impression Improvement (CGI-I), the Caregiver Strain Questionnaire (CSQ), electroencephalogram (EEG) spike frequency, overall power in frequency bands of an EEG, hemispheric coherence of EEG frequencies, stereotypic hand movement, eye tracking, QTc variability, heart rate variability (HRV), respiratory irregularities, and abnormal coupling of cardiac and respiratory function compared to control animals not suffering from said disorder.
17. The method of claim 1 , wherein said treatment reduces at least one symptom selected from the group consisting of anxiety, depression, cognitive impairment, cognitive dysfunction, memory loss, loss of spatial orientation, decreased ability to learn, decreased ability to form short- or long-term memory, decreased episodic memory, decreased ability to consolidate memory, decreased spatial memory, decreased synaptogenesis, decreased synaptic stability, deficits in executive function, deficits in cognitive mapping and scene memory, deficits in declarative and relational memory, decreased rapid acquisition of configural or conjunctive associations, decreased context-specific encoding and retrieval of specific events, decreased episodic and/or episodic-like memory, abnormal fear conditioning, abnormal social behaviour, repetitive behaviour, abnormal nocturnal behavior, seizure activity, abnormal locomotion, abnormal expression of Phospho-ERK1/2, abnormal expression of Phospho-Akt, and bradycardia.
18-34. (canceled)
35. The method of claim 1 , wherein the dose of the compound is from about 0.001 mg/kg to about 600 mg/kg.
36. (canceled)
37. The method of claim 1 , wherein said mammal is a human being.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/770,690 US20230301994A9 (en) | 2019-10-22 | 2020-04-24 | Bicyclic compounds and methods for their use in treating pitt hopkins syndrome |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962924452P | 2019-10-22 | 2019-10-22 | |
PCT/US2020/029739 WO2021080646A1 (en) | 2019-10-22 | 2020-04-24 | Bicyclic compounds and methods for their use in treating pitt hopkins syndrome |
US17/770,690 US20230301994A9 (en) | 2019-10-22 | 2020-04-24 | Bicyclic compounds and methods for their use in treating pitt hopkins syndrome |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220387426A1 US20220387426A1 (en) | 2022-12-08 |
US20230301994A9 true US20230301994A9 (en) | 2023-09-28 |
Family
ID=75620281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/770,690 Pending US20230301994A9 (en) | 2019-10-22 | 2020-04-24 | Bicyclic compounds and methods for their use in treating pitt hopkins syndrome |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230301994A9 (en) |
EP (1) | EP4048264A4 (en) |
JP (1) | JP2022553060A (en) |
KR (1) | KR20220106123A (en) |
CN (1) | CN115243688A (en) |
AU (1) | AU2020369431A1 (en) |
BR (1) | BR112022007636A2 (en) |
CA (1) | CA3158406A1 (en) |
CL (1) | CL2022001023A1 (en) |
CO (1) | CO2022006718A2 (en) |
IL (1) | IL292408A (en) |
WO (1) | WO2021080646A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230145397A (en) * | 2021-02-12 | 2023-10-17 | 뉴렌 파마슈티컬즈 리미티드 | Treatment of Prader-Willi Syndrome |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011037644A1 (en) * | 2009-09-25 | 2011-03-31 | Neuren Pharmaceuticals Limited | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy |
ES2797374T3 (en) * | 2013-07-25 | 2020-12-02 | Neuren Pharmaceuticals Ltd | Bicyclic neuroprotective compounds and methods for their use in the treatment of autism spectrum disorders and neurodevelopmental disorders |
-
2020
- 2020-04-24 JP JP2022523653A patent/JP2022553060A/en active Pending
- 2020-04-24 CN CN202080088567.2A patent/CN115243688A/en active Pending
- 2020-04-24 IL IL292408A patent/IL292408A/en unknown
- 2020-04-24 WO PCT/US2020/029739 patent/WO2021080646A1/en active Application Filing
- 2020-04-24 KR KR1020227017179A patent/KR20220106123A/en unknown
- 2020-04-24 BR BR112022007636A patent/BR112022007636A2/en unknown
- 2020-04-24 US US17/770,690 patent/US20230301994A9/en active Pending
- 2020-04-24 AU AU2020369431A patent/AU2020369431A1/en active Pending
- 2020-04-24 EP EP20879517.9A patent/EP4048264A4/en active Pending
- 2020-04-24 CA CA3158406A patent/CA3158406A1/en active Pending
-
2022
- 2022-04-22 CL CL2022001023A patent/CL2022001023A1/en unknown
- 2022-05-20 CO CONC2022/0006718A patent/CO2022006718A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022553060A (en) | 2022-12-21 |
CA3158406A1 (en) | 2021-04-29 |
EP4048264A4 (en) | 2023-11-29 |
BR112022007636A2 (en) | 2022-07-12 |
WO2021080646A1 (en) | 2021-04-29 |
KR20220106123A (en) | 2022-07-28 |
AU2020369431A1 (en) | 2022-06-09 |
IL292408A (en) | 2022-06-01 |
CN115243688A (en) | 2022-10-25 |
US20220387426A1 (en) | 2022-12-08 |
CO2022006718A2 (en) | 2022-08-09 |
CL2022001023A1 (en) | 2023-03-10 |
EP4048264A1 (en) | 2022-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11197856B2 (en) | Bicyclic compounds and methods for their use in treating autism | |
US7776876B2 (en) | Cyclic G-2Allylproline in treatment of Parkinson's disease | |
US20230301994A9 (en) | Bicyclic compounds and methods for their use in treating pitt hopkins syndrome | |
US20150258091A1 (en) | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals | |
WO2017035733A1 (en) | Conjugate of memantine and arctigenin, and composition and use thereof | |
US8519127B2 (en) | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | |
US20090263334A1 (en) | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | |
KR101052345B1 (en) | Pharmaceutical composition for treating neurotrophin-related diseases | |
US20240132511A1 (en) | Treatments of prader-willi syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING |
|
AS | Assignment |
Owner name: NEUREN PHARMACEUTICALS LIMITED, NEW ZEALAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GLASS, LAWRENCE IRWIN;COGRAM, PATRICIA;PILCHER, JONATHAN;SIGNING DATES FROM 20191106 TO 20191107;REEL/FRAME:060959/0308 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |